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Summary 
Breast cancer is the most common cancer among women in the United States, 
except skin cancer. 12% of women will develop invasive breast cancer during their 
lifetime. We sought to understand the transcriptional framework of breast cancer 
disease progression, including on-set, tumor growth and metastasis.  Ductal carcinoma 
in situ (DCIS) is referred to as stage 0 breast cancer and represents an initial proliferation 
of cancer cells within the breast ducts. In order to understand how DCIS progresses to 
invasive ductal carcinoma (IDC), we combined laser capture microscopy on human 
patient samples and RNAseq technology to profile their respective gene expression 
profiles. We completed hierarchical clustering of these samples, classified DCIS and IDC 
subtypes and identified differentially expressed genes that might serve as biomarkers. 
Next, we used mouse models of breast cancer metastasis, to assess the gene expression 
profiles of circulating tumor cells (CTCs) and metastatic tumor cells in order to identify 
genes that are regulators of the metastatic cascade. We identified Ptpn22, a protein 
tyrosine phosphatase, as a metastatic inducer. Knock-down of Ptpn22 decreased the 
lung metastatic burden in mice, due to an overall decrease in the number of CTCs in the 
blood circulation. Lastly, we developed a mouse model to assess clonal heterogeneity of 
primary tumor growth and metastasis. We identified clones that showed distinct 
specialization such as dominating in the primary tumor or metastasizing to the lung. 
Using this heterogeneity model, we identified Serpine2 and Slpi, two secreted protease 
inhibitors that are necessary and sufficient to program cancer cells for vascular mimicry. 
We think that vascular mimicry is one of the major drivers of metastatic progression. In 
summary, we identified multiple genes that might be relevant to human breast cancer 
progression and metastasis. 
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Chapter 1: Introduction 
 
Breast cancer 
Breast cancer initiates in the breast tissue, which is composed of glands for milk 
production, called lobules, and ducts, which connect the lobules to the nipple. In addition, 
there is connective, fat and lymphatic tissue. Cancers that occur within the ducts are known 
as ductal carcinomas and those that originate from the lobules are known as lobular 
carcinomas. According to the American Cancer Society, breast cancer is the most common 
cancer in females in western countries with one in eight women developing it (DeSantis et 
al. 2014). Approximately 60,000 new diagnoses of non-invasive in situ breast cancer and 
200,000 new cases of invasive breast cancer are expected among women in the United States 
in 2013 (Siegel et al. 2013). In addition, approximately 40,000 breast cancer deaths are 
expected among US women in the United States (Siegel et al. 2013). Nowadays, breast 
cancer accounts for 29% of all new cases of cancers and is the number two leading cause of 
cancer deaths (15% of all estimated cancer deaths), just behind lung and bronchus cancer in 
the United States (Siegel et al. 2014).  
 
Ductal Carcinoma In Situ (DCIS) 
Ductal carcinoma in situ (DCIS) is a spectrum of abnormalities that represent regions 
of proliferating neoplastic epithelial cells that line the breast ducts and have not yet invaded 
the ductal basement membrane. DCIS is the most common type of in situ breast cancer, 
representing around 80% of the in situ cases in the United States (Barnes et al. 2012; Virnig et 
al. 2010). It is believed that DCIS is the precursor to invasive ductal carcinoma (IDC). It is 
estimated that at least one-third of the cases diagnosed with DCIS will advance to invasive 
cancer if left untreated (Allred 2010). 
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The pathways of progression from DCIS to IDC are not well understood. The 
standard treatment of DCIS is breast-conserving surgery followed by radiation therapy to 
the intact breast. Approximately 20% of women who where diagnosed with DCIS and 
received treatment had local recurrence within 15 years, half of these cases were invasive 
carcinoma (Donker et al. 2013). On the other hand, those patients who were diagnosed with 
DCIS and were left untreated, approximately 35% of the patients developed IDC (Meyerson 
et al. 2011). Interestingly, the local recurrence is significantly higher in women under 40 
years at approximately 30%, whereas women over 40 years have a local recurrence of 
approximately 10% (Vidali et al. 2012). Thus, it is important to dissect the molecular 
pathways of DCIS in order to understand why some women progress to invasive carcinoma, 
relapse with DICS or IDC, or why young age is a big risk factor for local recurrence. By 
identifying molecular determinants of DCIS and IDC and correlating them with clinical 
annotations, we will be able to stratify patient outcome, and ultimately avoid over-treatment 
of patients diagnosed with DCIS.  
The DCIS incidence rate dramatically increased in the United States in the last 40 
years, from 1.87 per 100,000 women (1973 – 75) to 32.5 per 100,000 women in 2004, due to 
the widespread use of mammography. However, the number of new cases of invasive 
carcinomas has not decreased in the last decades (Virnig et al. 2010). One explanation might 
be that the outcome of DCIS is pre-programmed or that the treatment itself might promote 
progression to invasive carcinoma due to the use of ionizing radiation during therapy 
(Broeks et al. 2007). Over half of the patients diagnosed with DCIS will never develop 
invasive carcinoma, but all of these patients will most likely opt for treatment to avoid the 
risk. With very little knowledge about the causes of the transition between DCIS and IDC, 
there is an overwhelming need to identify, which DCIS lesions will develop into invasive 
	   3 
carcinoma. In order to identify these molecular determinants, we generated in-depth and 
unbiased gene profiling of multiple single DCIS and IDC lesions using RNAseq to probe 
their respective gene expression.  
 
Breast cancer metastasis 
The metastatic form of breast cancer, which can spread to lung, liver, bone, lymph 
nodes, and brain accounts for 90% of breast cancer deaths (Cifuentes and Pickren 1979; 
Steeg and Theodorescu 2008; Talmadge and Fidler 2010). Treatment of breast cancer often 
involves surgical removal of cancerous tissue, but, even after successful operation, 
recurrence rates are high (Karrison et al. 1999). While different approaches such as surgery, 
hormone therapy, chemotherapy and/or radiation therapy are used to eliminate metastatic 
cells, dormant solitary cancer cells can cause outbreaks after latency periods of 10 to 30 years 
(Aguirre-Ghiso 2007; Weckermann et al. 2001; Pfitzenmaier et al. 2006). To date, much 
research has focused on understanding the origins and mechanisms of breast cancer. 
However, the biology of disseminated tumor cells and their metastases are still poorly 
understood. 
In order to understand the mechanism of tumor metastasis, it is important to 
investigate every stage of the metastatic cascade. Metastasis is a stepwise mechanism 
starting with tumor cells invading through the basement membrane, following intravasation 
into the blood or lymphatic system and its subsequent survival, then extravasation into 
distant organ sites, and finally colonization into macro-metastases (Coomber et al. 2003). In 
order to metastasize, it is essential for cancer cells to complete all the stages described above. 
Even though the different steps of the cascade are nicely defined, the cellular and molecular 
mechanisms of dissemination are still poorly understood (Fein and Egeblad 2013). Advances 
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in next-generation sequencing (NGS) and low-input RNA library generation have created 
new possibilities to understand this metastatic cascade. RNAseq libraries can now be 
generated from very small amounts of cells, down to single-cell levels. Because of this, it is 
possible to dissect the dissemination process by performing transcriptome profiling of 
primary tumor cells, circulating tumor cells (CTCs) in the blood, and metastatic tumor cells 
at distant organ sites. Because the invasive behavior coincides with altered gene expression, 
by comparing the expression signature between these different compartments, we can 
identify genes that are responsible for certain steps of the metastatic cascade.  
 Although tumors originate from a clonal origin, a large degree of heterogeneity can 
be found in tumors. These cells vary in their morphological as well as their molecular 
features (Shipitsin et al. 2007; Fisher et al. 2013). Clones that have been isolated from a 
murine melanoma cell line and injected intravenously into syngeneic mice, displayed 
different metastatic potentials to the lung (Fidler and Kripke 1977). This indicates that the 
primary tumor is heterogeneous and more importantly that it contains different cell variants 
of varying metastatic capabilities. For this reason, it will be important to identify and study 
these individual cell variants as opposed to the bulk tumor population, since these cells will 
allow a greater insight into the biology of the metastatic process. 
 
Circulating tumor cells (CTCs) 
Metastatic spread is a complex process initiated by the dissemination of the primary 
tumor, subsequent seeding and engraftment of malignant cells at distant organ sites. In 
many cancer types, metastasis occurs through the lymphatic system, however in breast 
cancer, it has been found that 20 to 30% of patients have no lymph node metastases. This 
suggests that primary tumor cells can bypass the lymphatic system and can directly 
	   5 
disseminate through the blood stream, as circulating tumor cells (CTCs) (Pantel and 
Brakenhoff 2004). Another explanation is that the lymph node microenvironment might not 
be favorable for some tumor cells. CTCs are thought to be arrested in the G0 phase as 
demonstrated by an absence of the proliferation marker Ki67 (Pantel et al. 1993). Because of 
this, CTCs might be resistant against cytotoxic therapeutic agents (Braun et al. 2000). The 
presence of CTCs is also associated with a significant lower survival rate in breast cancer 
patients. The median overall survival was 18 months for CTC-positive patients, compared to 
27 months for CTC-negative patients using the Food and Drug Administration (FDA)-
approved CellSearch system for CTC enumeration (Zhang et al. 2012). Thus, much research 
is currently focused into developing tools to isolate and analyze CTC for prognostic and 
therapeutic purposes. It is believed that cancer outcome can be analyzed more precisely by 
molecular profiling of CTCs. However, whole-genome expression analysis of CTCs has not 
yet seen widespread use (Krebs et al. 2014). To date, only three studies were carried out 
with whole-genome transcriptome profiling, namely in prostate, melanoma and breast 
CTCs (Yu et al. 2013; Cann et al. 2012; Ramsköld et al. 2012). 
Sensitive methods have been developed to detect and isolate CTCs in the peripheral 
blood. CTCs can be distinguished and enriched from surrounding blood cells either by 
physical properties such as size and density or biological properties such as the expression 
of epithelial markers like EpCAM or cytokeratins (Alix-Panabières and Pantel 2014). The 
disadvantage of using epithelial markers to enrich for CTCs is that this might miss cancer 
cells that have undergone epithelial mesenchymal transition (EMT). Indeed, many CTC 
populations are enriched for mesenchymal cells in breast cancer (Yu et al. 2013). Thus, it will 
be important to include these cells in the isolation process.  
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Although systemic anti-cancer therapies such as chemotherapy are designed to 
eliminate metastatic cells, the current classification for treatment options is most often 
performed on the primary tumor. Increasing evidence shows that the phenotype and 
genotype of primary and metastatic tumor cells are discordant. For example, 
Krishnamurthy et al. reported a discordance in Her2 status between CTCs and primary 
tumors of early stage breast cancer by fluorescence in situ hybridization (FISH) 
(Krishnamurthy et al. 2013). 21% of patients showed acquired Her2 gene amplification in 
CTCs that had Her2 negative early stage breast cancer. Thus, it is possible that a very small 
fraction of primary tumor cells are Her2 positive and that these cells remained undetected 
by FISH. These cells might represent a potent metastatic subpopulation.  
Technological advances have enabled detection and characterization of CTCs from 
various solid tumors. So far, individual markers such as Her2 are used to analyze CTC 
populations. Currently, much effort is concentrated to carry out whole genome 
transcriptome analysis of CTCs using next generation sequencing. These studies will shed 
light into the genetic heterogeneity during metastasis and will offer new insights into the 
metastatic progression. 
 
Epithelial Mesenchymal Transition (EMT) 
It has been proposed by some investigators that in order for tumor cells to infiltrate 
the blood stream, they undergo an epithelial to mesenchymal transition (EMT). For this, 
epithelial cells can activate a transitory EMT program and convert into a mesenchymal state 
with increased migratory and invasive capabilities. It is thought that this stage is fluid, with 
many cells expressing epithelial and mesenchymal markers at the same time (Yu et al. 2013).  
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Fred Lillie first described the difference between epithelial and mesenchymal cells in 
1908. However, the mechanism of EMT was not defined until 1982 (Greenburg and Hay 
1982). EMT plays an important role in embryonic development during the reorganization of 
germ layers (Shook and Keller 2003), but has only been recognized to play an important role 
in tumor progression and metastasis in the last decade (Thiery 2002; Thiery et al. 2009).  
Many cell lines and mouse tumor models have demonstrated the importance of EMT 
during the metastatic cascade (Giampieri et al. 2009; Yang et al. 2004; Mani et al. 2008). 
Nevertheless, the EMT process in human cancers is difficult to identify since the cells that 
undergo EMT share many morphological and molecular features of mesenchymal stromal 
cells such as fibroblasts (Thiery 2002). Several EMT genes such as Twist, Snail and Slug have 
been described to have a role in metastasis (Emadi Baygi et al. 2010; Hotz et al. 2007). 
Therefore, by targeting EMT genes it may be possible to inhibit the EMT program and 
thereby preventing the metastatic progression.  
 
Tumor Microenvironment 
Solid tumors do not only represent a random assembly of cells but can be thought of 
as a separate organ. All of the cell types comprising an organ can also be found in tumors. 
The different tumor niches can be defined by (1) members of the extracellular matrix (ECM) 
(2) stromal cells including mesenchymal supporting cells, cardiovascular cells as well as 
cells of the immune system and (3) peptide factors covering growth factors, chemokines, 
cytokines and metabolites (Egeblad et al. 2010). All of these different factors play an 
important role in the tumor microenvironment, which in turn have a great impact on the 
regulation of cellular movement and assembly during tumorigenesis (Bissell and Radisky 
2001; Wiseman and Werb 2002; Bissell and Labarge 2005). While some of these factors have 
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tumor-promoting effects, others have strong inhibitory effects on tumor growth. Due to 
their rigid barrier, normal epithelium and fibroblasts have a tumor inhibiting effect in 
hyperplastic tissues. Nevertheless, in the process of tumor development carcinoma-
associated fibroblasts support tumor growth and have large effects on changes in the ECM 
(Orimo et al. 2005).  
Cells of the immune system play a role in tumor-inhibition as well as in tumor-
promotion. Inflammatory cells like neutrophils and macrophages are recruited to the 
primary tumor due to their innate and adaptive immune response (Fridlender et al. 2009). 
Based on their polarization they are either pro- or anti-tumorigenic. Mast cells have been 
described to promote angiogenesis and thereby promoting tumor development (Coussens et 
al. 1999). Most dendritic cells support immunosurveillance and are therefore tumor-
inhibiting factors (Knight et al. 1985; Mayordomo et al. 1995). However, natural killer cells 
as well T-cells can either inhibit or promote tumor growth (DeNardo et al. 2009; Casares et 
al. 2003; Curiel et al. 2004; Girardi et al. 2001). Since immunoglobulins, produced by B cells, 
initiate the inflammatory response they rather inhibit tumor development (Inoue et al. 2006). 
The metastatic process is also strongly connected to the tumor microenvironment. 
Fibronectin is strongly expressed on vascular leakage sites promoting the exit of tumor cells 
from the vasculature (Kaplan et al. 2005). This further promotes the formation of metastases. 
It is thought that activated platelets cover CTCs to protect them during their travel through 
the blood vessels as well as their adherence to endothelial walls in distant organ sites 
(Camerer et al. 2004; Nieswandt et al. 1999).  
It is still unknown what role the microenvironment plays in the transition from DCIS 
to IDC. There is evidence that stromal cells might play a role in this transition, since a 
macrophage response signature is associated with a higher grade of DCIS, decreased 
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expression of estrogen receptor (ER) and progesterone receptor (PR) and an increased rate 
of p53 mutations (Sharma et al. 2010). In addition, periductal macrophages and 
myofibroblasts have been associated with the initial steps of invasive carcinomas by up-
regulating the expression of the plasminogen activation system and MMP-13 (Nielsen et al. 
2007; Fakhrejahani and Toi 2012). These studies indicate that the stromal compartment 
might possess a role in the transition from DCIS to IDC and thus might be useful as 
predictive markers.  
 
4T1 murine breast cancer mouse model 
The 4T1 breast cancer cell line series (4T1, 66cl4, 4T07, 168FARN and 67NR) have 
been isolated from a single primary tumor of a BALB/c mouse. These mice have been 
infected with the mouse mammary tumor virus (MMTV), which has properties similar to 
other RNA tumor viruses and is present in mothers’ milk. By expression of key host genes 
in the mammary stem cell pre-neoplastic epithelium, a tumorogenic phenotype is induced. 
Interestingly, the 4T1 cell lines differ in their metastatic potential (Aslakson and Miller 1992). 
Additionally a difference in the in vitro growth rate, sensitivity to chemotherapeutics as well 
as MMTV expression distinguishes the different cell lines (Pulaski and Ostrand-Rosenberg 
1998; Ostrand-Rosenberg et al. 1998). The 4T1 cell line resembles most reliably the human 
stage IV breast cancer in respect to growth kinetics, pathology, invasiveness, poor 
immunogenic phenotype as well as spontaneous metastasis formation (Pulaski et al. 2000). 
While 4T1 and 66cl4 cell lines lead to lung metastasis upon orthotopical 
transplantation of cells into the mammary gland of BALB/c mice, no overt metastases can 
be found in mice injected with 4T07, 168FARN and 67NR cell lines. The 4T1 cell line is 
highly aggressive and metastasizes spontaneously to lung, liver, bone and brain in BALB/c 
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animals. The 66cl4 cells mostly metastasize through the lymphatic system to the lung and 
these cells were mutagenized with EMS. The 4T07 and 168FARN cells were also 
mutagenized with EMS and the 67NR cell line was not treated with any mutagen (Miller et 
al. 1983b; Dexter et al. 1978; Aslakson and Miller 1992; Miller et al. 1986).  
 
Tumor heterogeneity 
 In the early 1800s Rudolf Virchow was one of the first people to observe 
morphological heterogeneity in tumor tissues (Brown and Fee 2006). The first concrete 
evidence for tumor heterogeneity was discovered in the 1950s, when they identified 
different cell populations throughout the tumor (MAKINO 1956). Studies in the 1970 
showed evidence for distinct subpopulations of tumor cells, which differed in 
tumorigenicity, resistance to therapy and metastatic potential (Fidler and Kripke 1977). This 
was perceived with skepticism, since it was initially thought that tumors originated from a 
single mutated cell and thus should be monoclonal (Fialkow 1979). In 1976, Peter Nowell 
proposed a clonal evolutionary model of cancer development and subsequently the concept 
of tumor heterogeneity received broader acceptance (Nowell 1976). Nowadays we know 
that tumor heterogeneity is a consequence of somatic evolution of cancer cells caused by 
stepwise clonal expansions. Single tumor cells undergo developmental changes during their 
growth by acquiring random mutations. These tumor cells undergo positive selection for 
advantageous mutations and negative selection for harmful mutations. In the case of an 
evolutionary advantage, the generated cells can outcompete their less fit parental and sister 
clones (Hanahan and Weinberg 2000). Because of this, genetically related clones with 
slightly different genotypes and phenotypes can cohabit in the same tumor (Shipitsin et al. 
2007). This polyclonal composition is advantageous for the tumor, since the molecular 
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heterogeneity increases the pool of genetic variants that undergo selection and thus 
increases the chance of survival for one or few subclones (Fisher et al. 2013). With different 
subpopulations, together they can cope with a wider variety of environmental factors. 
Overall, this can results in the generation of different superior subpopulations in one tumor.  
 The ability of tumor cells to accumulate DNA mutations is greatly increased 
compared to normal cells. This is known as genomic instability and is one of the hallmarks 
of cancer. Other hallmarks include sustained proliferative signals, ability to evade growth 
suppressors, replicative immortality, resistance to cell death, immune evasion, promotion of 
inflammation, angiogenic potential, increased motility, metastatic ability, and altered 
cellular metabolism (Hanahan and Weinberg 2011). Heterogeneity can be separated in a 
mosaic pattern throughout the tumor or in different subpopulations that are regionally 
separated. With different environments generated by hypoxia, angiogenesis, necrosis and 
growth, it would be very surprising if all tumor cells were identical (Gerlinger and Swanton 
2010). Thus, clonal composition can not only differ in the primary tumor, but between the 
primary tumor and metastases or tumors of the same histopathological subtype (Komaki et 
al. 2006).  
 The development of cellular heterogeneity within a tumor is a complex process. 
Driver and passenger mutations are acquired due to the increased instability of the genome. 
On one hand, driver mutations increase the fitness of a clonal cell and confers a selective 
advantage, passenger mutations have no negative effects on the proliferation potential. 
Currently, only driver mutations stand in the central focus of research, when trying to 
understand the genetic basis of cancer.  
 Intratumor heterogeneity poses a great challenge for personalized medicine and 
selection of treatment. Thus it is important to develop methods to detect tumor 
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heterogeneity in order to identify and model therapeutic responses and disease outcome. 
New technologies are being used and developed in order to identify tumor heterogeneity. 
 
Approaches to identify tumor heterogeneity 
  In order to gain a deep understanding into the architecture of cancers, genomic 
analyses are necessary. Early studies based on Sanger sequencing were insufficient to 
analyze tumor heterogeneity because sequencing depth was limited and rare 
subpopulations could not be detected. In addition, extraction of tumor samples always yield 
stromal cells, such as fibroblasts or immune cells. This can complicate genomic DNA 
isolation of tumor cells and can provide false positives in the sequencing results. In addition, 
analyzing bulk DNA from tumors can lead to loss of detecting cellular heterogeneity at a 
single cell level. Nevertheless, through the development of novel technologies within the 
last few years, we are able to examine the clonal composition of cancers and tumor 
heterogeneity at a high resolution.  
 
Allele frequency quantification 
 The first approach to study clonal evolution in cancer using next-generation 
sequencing (NGS) was developed by Elaine Mardis in 2009 (Mardis et al. 2009). The 
technology is based on the identification of somatic mutations and subsequent calculations 
of allele frequency. First, the genomes of an acute myeloid leukemia (AML) tumor and 
normal skin were sequenced using NGS. Then, single-nucleotide variants (SNVs) were 
detected and compared to single-nucleotide polymorphisms (SNPs). After validation, deep 
sequencing reads were obtained of each somatic mutation in order to calculate the allele 
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frequency of variants in the tumor cell population. With this, groups of mutant allele 
frequency could be identified and this was compared to normal skin samples. 
 Using the same approach, the same group also analyzed the heterogeneity of tumor 
progression in basal breast cancer by looking at the allele frequency of the primary tumor 
and metastases (Ding et al. 2010). One of the questions they wanted to address was whether 
the metastasis process requires specialized cells generated by the primary tumor or whether 
the necessary mutations occur only after the cell has arrived at the metastatic site. For this, 
genomic DNA was extracted from peripheral blood, the primary tumor, brain metastasis 
and an early passage xenograft. Most of the identified mutations were found throughout all 
cancer samples, but some mutations were highly enriched in the metastases and the 
xenograft. Interestingly, these genes were involved in migration, invasion and 
tumorigenesis (Chan et al. 2008). Several mutations were also only found in the metastases, 
but not detected in the primary or xenograft tumor genomes. The authors were able to 
conclude a hierarchical model of genomic changes with mutations occurring at different 
levels during disease progression, constituting to a considerable genetic heterogeneity of the 
primary tumor. Mutation frequencies were lower in the metastases and xenograft compared 
to the primary tumor, indicating that only certain cells with distinct mutations were able to 
form metastases or grow as a xenograft. Interestingly, mutation frequencies often 
overlapped between these metastases and xenografts, highlighting a similar selection 
process between both environments. Thus, in summary, the potential of forming metastases 
seems to already be embedded in the cancer cells when they separate from the primary 
tumor. However, clonal evolution continues at the site of metastases and contributes to the 
overall metastatic phenotype. Using this approach, the group also analyzed the clonal 
composition in relapsed AML (Ding et al. 2012).  
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 Overall, these studies give strong evidence to the concept of tumor heterogeneity, 
which is a step-wise accumulation of mutations. Limitations of this method are that it is not 
able to detect rare mutations at a single-cell level, due to low sequencing coverage of the 
whole genome. Furthermore, this method is unable to uncover more complex clonal 
relations. Lastly, it is impossible to do functional studies on these subpopulations, because 
they can not be easily isolated.  
 
Single nucleus sequencing 
 Another approach to trace tumor development by studying mutations in different 
subpopulations of tumor cells was established by Nicholas Navin and James Hicks (Navin 
et al. 2010). Their goal was to construct a phylogenetic lineage of cancer progression by 
comparing data from divergent clones of a primary breast tumor and its metastases. For this, 
they macro-dissected solid tumors into sectors and then isolated nuclei from each sample. 
Fluorescence activated cell sorting (FACS) was used to sort nuclei according to differences 
in their genomic DNA content as measured by DAPI intensity (Corver et al. 2008). DNA was 
isolated from the flow-sorted nuclei and then used for whole-genome copy number 
variation analysis by representational oligonucleotide microarray analysis (ROMA) (Lucito 
et al. 2003). This form of comparative genomic hybridization (CGH) allows for analysis of 
copy number profiles and chromosome breakpoint patterns. Thus, samples of different 
tumor sectors and tumor subpopulations based on DNA content were compared to assess 
heterogeneity throughout the tumor. 
 Using this method, Navin and Hicks were able to see that slightly more than half of 
the analyzed breast tumors were classified as polygenomic and displayed considerable 
heterogeneity. The separation of subpopulations based on DNA content matched the 
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profiles that were seen using the CGH analysis. Within one tumor most chromosome 
variations were very similar between the subpopulations, which strongly indicate that all 
subpopulations had a common clonal origin. On the other hand, some tumors contained 
subpopulations that shared almost no chromosomal breakpoints. Overall, they were able to 
conclude that mutations are accumulated as the tumor progresses and genomic 
heterogeneity can serve as a permanent record of mutations, unless a whole chromosome is 
lost. A major drawback is the limitation of analyzing mixtures of cell populations. Different 
clones can only be separated based on regional sectors, surface markers or ploidy to conduct 
genome-wide comparisons.  
 In order to overcome this limitation, Navin and Hicks used single-nucleus 
sequencing (SNS) in their subsequent study (Navin et al. 2011). For this, nuclei were isolated 
from whole tumor samples by FACS. Genomic DNA from single cells was amplified by 
means of whole genome amplification (WGA), sequenced using NGS and copy number 
variations analyzed. This allowed for a closer examination of individual cells of different 
tumor subpopulations and indeed revealed that each subpopulation is comprised of cells 
with highly similar copy number profiles. Although every subpopulation shared attributes 
with others, they still showed distinct genetic profiles. This supports the notion that all 
subpopulations diverged from a common ancestor at an early stage of tumor development. 
They were also able to analyze the heterogenic properties of matched primary tumor and 
metastases. Interestingly, they saw that the metastatic tumor was seeded by only one cell of 
the primary tumor, which developed with little further evolution. Although similar, the 
metastatic cells clearly separated from the primary tumor cells, indicating that there was no 
intermixing between the two populations after formation of the metastasis. Analogous 
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results have been reported in other studies (Liu et al. 2009; Hovey et al. 1998; Israeli et al. 
2004; Ding et al. 2010).  
 The study by Navin and Hicks strongly support the clonal evolution model in which 
tumor cells proliferate until an advantageous genotype is achieved, whereupon the clone 
will undergo clonal expansion and form the mass of the tumor. Furthermore, the study 
confirms the knowledge that genomic profiles of metastases are very similar to their 
primary tumors and probably emerge from individual cells out of the tumor mass at a late 
stage in cancer development. After seeding, the metastases only undergo further mutations, 
but usually don’t develop new chromosomal breakpoints. While the SNS method succeeds 
in profiling single cells, the thin sequence coverage makes this analysis problematic. As an 
alternative, a combination of multiple cells from a defined subpopulation could be used to 
enhance regional and global genome coverage. In addition, since all SNS studies only 
analyze a limited number of single cells, compared to the billion of cells a tumor or 
metastasis has, the observed picture might be missing key components. The most lethal 
tumorigenic subpopulation must not always be the most prominent fraction and thus, it is 
possible that these SNS studies are not be able to identify such populations. 
 
Barcoding 
 In 2013, Nolan-Stevaux utilized DNA barcoding technology to study tumor 
heterogeneity (Nolan-Stevaux et al. 2013). For this, they used lentiviral barcoding to 
measure the growth heterogeneity of cancer cells in xenografts in immune-deficient mice. 
They infected colorectal cancer cell lines with a lentiviral barcode library, containing unique 
nucleotide barcodes. Barcoded cells were injected into mice, xenograft tumors were resected 
and genomic DNA was extracted. The barcode was then identified using NGS. Analysis of 
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the in vivo distribution revealed that 75% of the injected cell clones did hardly engraft in 
mice and only made up 1% of the overall tumor mass. On the other hand, 7% of the injected 
tumor clones were able to divide at an above-average rate, leading to around 80% of the 
total number of tagged cells in the tumor. The phenomenon that a small number of 
individual cancer cell clones from a heterogeneous pool takes over the entire tumor after 
implantation is termed clonal dominance. As an explanation, the authors presumed the 
interplay of two stochastic contributing factors. For one, each cell in a homogeneous cancer 
population exhibits a slightly different phenotypic state, which ultimately converge to 
equilibrium (Gupta et al. 2011). Second, since the tumor poses a highly diverse environment 
for cells with varying regions of hypoxia and necrosis, clones in a favorable area of the 
tumor (e.g. close to blood vessels), exhibit a positive selection compared to clones in a less 
favorable geographic area. The authors came to the conclusion that clonal dominance is 
driven rather by randomness than by genetic differences, referring to a study in 
transplanted xenografts in which cells showed a statistically oscillating behavior (Kreso et 
al. 2013). Overall, Nolan-Stevaux employed a new and promising method for tracking 
different cancer cell clones in vivo, which could have a number of different applications in 
therapeutic research, for example to study the susceptibility and resistance of different 
clones during cancer treatments. One of the major drawbacks of this study is that they only 
used 3 animals for their study. It is possible that the reason why the authors did not detect 
an overlap of the dominant clones between the replicates and thus concluded it is driven by 
randomness is due to the limited amount of mice they used in their study. 
 The method of barcoding is a promising tool in characterizing tumor subpopulations 
and studying the development of tumor heterogeneity. We decided to employ the barcode 
strategy on the 4T1 murine breast cancer cell line in order to identify and track individual 
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clones throughout tumor progression and metastasis. Combining this approach with 
experimental cancer therapies can shed light on possible new targets and improved cancer 
treatment strategies. 
 
Clinical impact of tumor heterogeneity 
 Intra-tumor heterogeneity has large implications for the treatment of cancer patients. 
Currently, cancer diagnosis heavily relies on biopsies of a very small region of a tumor 
during diagnosis. However, the concept of tumor heterogeneity renders this method almost 
impossible. Presently, pathologists examine multiple sections from the same tumor, but 
report only the highest grade. This highly underestimates the somatic mutational landscape 
of a tumor. The assumption that tumor characteristics are passed on to metastases during 
disease progression has not always been proved correct, as seen in the studies presented 
above. This shortcoming is one of the major reasons, why cancer diseases are able to adapt 
to a changing microenvironment and eventually resist advanced drug therapy (Keats et al. 
2012; Schuh et al. 2012).  
 Currently, targeted therapy usually tries to exploit a tumor’s dependency on critical 
proliferation or survival pathways. This has led to significant prolonged survival rates and 
overall benefit for cancer patients. This approach can be effective, when clonal cell lines 
cooperate to enhance tumor growth (Snuderl et al. 2011; Bach et al. 2001). Here, several 
subclones occupy different niches within the microenvironment, which increases the 
survival of the entire tumor structure. Relationships between single subpopulations are 
complex and can vary, but each clone influences the growth of the whole tumor. Targeting 
one subpopulation can thereby weaken the entire tumor complex and can lead to temporary 
improvement of tumor burden. However, most studies come to the conclusion that tumor 
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heterogeneity leads to overall decreased sensitivity to targeted therapeutics (Szerlip et al. 
2012). As different tumor subclones can differ greatly in their mutation and cellular 
signaling pathways, often only few clones can be targeted efficiently. As other remaining 
clones usually take over quickly, the clinical benefits are rather short-lived (Saunders et al. 
2012). 
 In order to develop therapies targeting a broader range of subclones, driver 
mutations need to be identified, which occur early during tumor development. As these 
mutations are ubiquitous, therapeutic approaches targeting these mutations have the 
potential to be much more effective (Saunders et al. 2012; Swanton 2012). However, even 
targeting these driver events might not have a significant effect on therapy outcome, since 
small tumor subpopulations continue to evolve and could develop drug resistance. This has 
been observed previously for mutated EGFR in non-small cell lung cancer (Su et al. 2012; 
Lynch et al. 2004). Thereby, a later mutation was able to abrogate the tumor’s dependency 
on an earlier occurring driver mutation. Thus, it is likely that therapeutic success and patient 
survival is largely dependent on the frequency of somatic mutations along with the number 
of subpopulations in the tumor. 
Tumors developing drug resistances are indeed the biggest problem faced currently 
by oncologists. Once metastatic solid tumors have formed, almost all cancer patients die of 
their disease. Usually drug resistance is conferred by a small subpopulation harboring one 
specific genomic mutation that can evade first line treatment, as it was seen in a study on 
AML (Ding et al. 2012). 
Although it is largely known that conventional therapies are oftentimes not able to 
cure cancer, they are used to prolong survival times of many patients. Indeed, in some cases 
tumors respond very well to treatment. However, in worst cases chemotherapy even 
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increases the chances of relapse by inducing selective evolution of tumor clones. It was 
observered that interval cytotoxic chemotherapy increases subclonal evolution, even 
contributing to relapse occurrences (Ding et al. 2012). This is not surprising, considering that 
chemotherapy causes damaging of the DNA and increases overall genomic instability. 
While in some cases drug resistance is developed over time, these mutations can 
even exist before treatment and impart significant selective advantage of one population. 
After targeted therapy kills previous dominant clones, this population can proliferate and 
take over the tumor. It is known that some patients with chronic myeloid leukemia possess 
an Imatinib-resistance in the BCR-ABL fusion gene in some subclones (Shah et al. 2002). 
Thus, while the standard used Imatinib therapy kills most of the leukemic cells, a resistant 
minority can proliferate and ultimately lead to the death of the patient. Knowledge of every 
subpopulation in a tumor would enable the application of individual combinatorial 
approaches, in order to target all subclones at once. This is most likely achieved with a 
combination of several cancer drugs, delivering an all-out attack. 
The viral barcoding strategy is a promising approach to study the effects of tumor 
growth, metastasis, drug resistance and microenvironment on different tumor populations 
in mouse models. We combined the barcode strategy with single cell sorting of individual 
clones so that each clone can easily be isolated and tested functionally. This knowledge can 
then be translated into potential clinical approaches.  
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Chapter 2: Transcriptional framework of ductal carcinoma in situ (DCIS) 
 
Ductal carcinoma in situ (DCIS) is a spectrum of abnormalities that initiate in the 
cells that line the breast ducts (Barnes et al. 2012; Virnig et al. 2010). DCIS is considered a 
noninvasive form of breast cancer because the abnormal cells are still confined to the 
original layer of cells. DCIS may or may not progress to invasive ductal carcinoma (IDC). 
We wanted to combine laser capture microscopy and low input RNAseq, in order to profile 
human patient samples diagnosed as having DCIS or DCIS with micro-invasion. We were 
able to process DCIS, IDC, normal ducts and stroma (any surrounding connective tissue) 
from multiple patient samples and generated high-quality RNAseq libraries. Hierarchical 
clustering of these samples revealed that all of the DCIS samples clustered tightly together, 
whereas the IDC samples clustered in multiple subgroups. We were able to identify 
subtypes of DCIS and IDCs based on existing intrinsic breast cancer markers. It is our hope 
that this will lead to predictors for progression of DCIS to IDC. Lastly, we carried out 
differential expression between DCIS vs. normal ducts and DCIS vs. IDC samples in order 
to identify genes implicated in disease progression and invasion. Some of these 
differentially expressed genes have been shown to be involved in metastasis and we are 
hoping that this will lead to the identification of new biomarkers.  
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Transcriptional profiling of DCIS 
 
We wanted to evaluate the biology of human DCIS through transcriptome 
sequencing (RNAseq). We used next-generation sequencing to generate gene expression 
profiles from single DCIS lesions of human patient samples. We wanted to know whether 
DCIS lesions could be classified to subgroups, similar to the ‘intrinsic’ subtypes of breast 
cancer. In addition, we wanted to compare individual DCIS lesions to IDC regions and 
normal tissue from the same patient in order to identify genes that might be responsible for 
the invasive phenotype.  
We have established a collaboration with the Duke SPORE breast tumor bank (Dr. H. 
Kim Lyerly and Dr. Joseph Geradts), which contains 7,000 core needle samples from 1,700 
patients, including 222 cases pure DCIS tumors. These samples are pathologically confirmed 
and annotated with HER2, ER, PR, and lymph node status. The full clinical annotation of 
these specimens is currently in progress.  
We generated large-scale transcriptome datasets that describes the molecular events 
that occur in DCIS and invasive carcinoma (Fig 2.1a,b). Overall 10 DCIS tumors were 
processed for transcriptome sequencing. For each DCIS tumor, we isolated multiple 
distinctive DCIS lesions, invasive carcinoma, stromal cells and normal tissue using the Leica 
LMD 7000 laser capture microscope and processed them for RNAseq. The histology of each 
DCIS lesion was documented and post-analyzed by the pathologist, Dr. Joseph Geradts, at 
the Duke SPORE breast tumor bank.  
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Figure 2.1 Workflow of DCIS isolation and RNAseq library construction  
(a) Schematic of RNAseq library construction. The Clontech SMARTer Ultra Low 
technology uses oligo(dT) priming to generate cDNA from as low as one single cell. After 
sonication of the cDNA, the NuGEN Ovation Ultralow System is used to generate Illumina 
sequencing libraries. (b) Examples of individual DCIS lesions being cut by the laser capture 
microscope. For each sample, three serial sections are individually cut and processed to 
account for biological replicates.    
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Clustering of transcriptome data 
From the 10 breast tumor patient samples we processed, we were able to generate 
117 RNAseq libraries that passed quality control (high percentage of unique mappers, Table 
2.1). Five of these patient samples contained only pure DCIS and the other set of five 
samples contained a mix of DCIS and IDC. Overall, the samples were derived from multiple 
DCIS and IDC lesions, stroma and normal tissue (Fig 2.2). Each of these samples were 
prepared from roughly 50 – 100 cells. After mapping and gene abundance estimation, all 
genes showing at least 10 reads per million per nucleotide (RPM) were used to cluster the 
transcriptome data (Fig 2.3). The most notable cluster is that encompassing nearly all DCIS 
samples in the dataset (labeled with blue bars below the dendogram). Within the DCIS 
cluster, the profiles cluster by patient origin (denoted by the color of the sample name). For 
each sample, there are two to three biological replicates, which can be identified by the same 
sample name. The biological replicates almost always cluster together. The other notable 
clusters in Figure 2.3 are those that comprise most of the normal and stromal tissues 
(denoted by black and green bars, respectively). Most of the IDC samples (denoted by red 
bars) clustered away from the DCIS samples and were closer to the normal and stromal 
tissues. There was a smaller cluster of IDC samples to left of the DCIS cluster, which we 
denoted IDC-A and a bigger cluster of IDC samples to the right of the DCIS and stroma 
cluster, which we denoted IDC-B. There could be several explanations for these multiple 
IDC subgroups. There might be multiple molecular subtypes for IDC, whereas all DCIS 
lesions might be more similar to each other. Because we only had a limited number of IDC 
samples, we might not able to the see the full spectrum of different subgroups with the IDC 
class. Another explanation might be a technical limitation for isolating IDC lesions. Because 
the cells have broken off from a relatively pure DCIS lesion, they are mixed with other  
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Table 2.1: Overview of the number of samples collected, processed and analyzed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Number of patient samples dissected  10 
Number of RNAseq libraries constructed 141 
Number of RNAseq libraries that passed 
quality control  117 
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Figure 2.2 Histological comparison between DCIS and IDC  
(a) Pre- and post-cut of a DCIS lesion (b) Pre- and post-cut of an IDC lesion. Note the 
heterogenous cell population within the IDC lesion.  
 
 
 
 
 
  
a 
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Figure 2.3 Sample clustering based on transcriptome data  
RNAseq libraries were clustered based on their respective gene expression (only genes of at 
least 10 rpm). Sample types (DCIS, IDC, normal ducts, stroma (any surrounding connective 
tissue cells)) are color-coded. For each sample, there are two to three biological replicates, 
which are denoted by the same sample name. Sample names are color-coded based on the 
patient origin. Most DCIS samples cluster together, whereas stroma, normal and IDC 
samples are broken into several clusters.   
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stromal and normal cells (Fig 2.2). Thus, there might be some stromal contamination 
associated with the IDC samples and this might be the reason, why they cluster closer to 
normal and stromal samples. For future analysis, it will be important to quantify the 
amount of stromal contamination from each IDC lesion and discard the samples that 
possess a high stromal infiltration.  
In addition, the sample type (DCIS, IDC, normal, stroma) can be separated by a 
principal component analysis (Fig 2.4a). If we look at the patient origin of the same principal 
component analysis, we can see that there is no clear separation based on patient ID (Fig 
2.4b). Thus, we can exclude large batch effects on these RNAseq libraries. However, there 
are small patient-to-patient variations and it will be important to account for these. We are 
collaborating with Prof. Molly Hammell to use a generalized linear model (GLM) to 
improve the analysis on our differential expression (Auer and Doerge 2010). Basic 
differential analyses handles simple pair-wise comparisons, for example DCIS vs. IDC, but 
these analyses can’t account for other variations. GLM performs multi-variable comparisons 
and calculates the variation contributed by each variable (for example tumor type or 
patient). We can then determine the major contributor of variation on the gene expression 
alterations and then account for these effects.  
 
Subtype classifications based on breast cancer markers 
 We wanted to see if we could identify any DCIS/IDC subtypes using existing 
‘intrinsic’ breast cancer markers. For this we used PAM50, which uses a minimal gene set of 
50 genes in order to classify subtypes of breast cancer (luminal A/B, Her2-enriched, basal 
and normal-like subtypes) (Parker et al. 2009; Tibshirani et al. 2002). This gene set has a high 
agreement with other larger gene sets previously employed for subtyping and is now  
	   29 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure 2.4 Principal component analysis on transcriptome data  
(a) Principal component analysis separates samples based on type. (b) Principal component 
analysis separates poorly based on patient ID. There seems to be no large batch effects.  	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commonly used (Esserman et al. 2012; Gonzalez-Angulo et al. 2012; Perou et al. 2000). We 
were able to cluster the samples into several subtypes (Fig 2.5). Sample names are color-
coded (blue for DCIS, red for IDC and black for normal). We were able to identify a cluster 
with Her2-enriched DCIS with high expression of HER2. A second cluster was represented 
by ER/PR-positive DCIS and IDC with high expression of estrogen receptor 1 (ESR1/ER) 
and relatively high expression of progesterone receptor (PGR/PR). In addition, a 
normal/normal-like cluster with samples showing strong expression of cytokeratins (CK5, 
14, and 17) and a basal-like IDC cluster showing hallmarks such as low expression of 
NDC80, ANILIN, MELK and CEP55 were identified. Lastly, there is a mixed DCIS and IDC 
group that is characterized by strong expression of SFRP1.  
In summary we were able to generate subtypes of DCIS and IDC based on existing 
breast cancer markers. The DCIS samples seemed to fall either to the HER2-enriched cluster 
or to the ER/PR-positive cluster. The IDC samples fell into more clusters than the DCIS 
samples. However, a large proportion of the IDC samples fell into the basal-like cluster. 
Almost all of the normal samples were clustered into a single subtype. It will be interesting 
to correlate these subtypes with clinical annotations of our samples. The hope is that we will 
be able to predict clinical outcome based on the subtype classifications of the DCIS and IDC 
samples. 
 
Differential gene expression analysis 
We wanted to look at differential expressed genes between DCIS vs. normal and 
DCIS vs. IDC in order to identify genes that might regulate the DCIS or invasive phenotype. 
Table 2.2 shows the top 20 up-regulated genes in all DCIS vs. normal (based on abundant 
genes above 100 RPM). Not surprisingly, ERBB2/HER2 is highly up-regulated in DCIS  
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Figure 2.5 Subtype classifications of DCIS and IDC 
The PAM50 gene list was employed in order to generate subtype classifications of all DICS, 
IDC and normal samples. DCIS samples are color coded in blue, IDC samples are in red and 
normal samples are color coded in black. Five clusters of samples were identified using this 
gene set.  
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Table 2.2: Top 20 up-regulated genes in DCIS vs. normal 
 
 
 
  
Gene ID Normal [counts] DCIS [counts] log2 fold change p value 
S100A7 3.292807589 2263.628097 9.425103022 7.88E-07 
DCD 5.992251298 1353.854982 7.819759371 0.001692923 
CLEC3A 4.828873426 467.7263374 6.59783421 1.88E-05 
SLC30A8 8.467888827 700.853813 6.370967413 7.10E-14 
CPB1 34.1629011 2264.310401 6.050497439 0.008263425 
S100P 7.047804263 353.9492472 5.65022484 2.07E-07 
ABCC11 8.666465162 330.6280151 5.25362149 0.002430132 
GSDMB 5.091157587 162.9579835 5.000362501 0.00033062 
PLA2G2A 3.569441084 113.8062982 4.9947384 0.00038475 
SOWAHA 5.10104815 139.1098849 4.76928741 1.72E-06 
S100A8 129.2339085 2932.441724 4.504045878 0.005038106 
ERBB2 195.4103404 3261.090965 4.060775968 8.75E-07 
THRSP 9.278249621 153.1166878 4.044635056 0.013033397 
CST4 6.410298083 100.9750141 3.977463092 0.004450301 
FADS2 12.47273338 174.7953615 3.808817332 0.005894755 
GRB7 14.77495461 202.0266309 3.773319876 5.97E-06 
CYP4Z1 18.07051107 241.8349511 3.74231355 0.015515287 
SERHL2 10.53707953 137.358577 3.70440003 0.001306822 
CYP2B7P1 17.14755243 211.9770043 3.627833194 0.00054054 
SCD 186.1981021 2260.790772 3.60191721 3.52E-07 
Based on abundant genes above 100 rpm 
	   33 
compared to normal tissue. The highest log2 fold change was observed for S100 Calcium 
Binding Protein A7 (S100A7). This gene has previously been identified as a molecular 
marker for DCIS (Porter et al. 2003; Emberley et al. 2004; Petersson et al. 2007). Next, we 
wanted to identify genes that were overexpressed in all DCIS vs. IDC. Because we identified 
two major clusters of IDC (Fig 2.3), we compared all DCIS to the IDC-A cluster and all DCIS 
to the IDC-B cluster. As a reminder, IDC-A represents the smaller cluster of IDC samples to 
left of the DCIS cluster and IDC-B represents the bigger cluster of IDC samples to the right 
of the DCIS and stroma cluster. Table 2.3 and 2.4 shows the top 20 up-regulated genes in all 
DCIS vs. IDC-A and all DCIS vs. IDC-B respectively (based on abundant genes above 100 
RPM). Some of the overexpressed genes have been implicated with invasion or metastasis. 
For example, lymphotoxin beta (LTB) belongs to the TNF superfamily and has been 
associated with higher expression in lymph node metastasis compared to matched primary 
papillary thyroid carcinoma (Cerutti et al. 2007). E-selectin (SELE) was shown to be higher 
expressed in metastatic colorectal cancer cells compared to local non-metastatic variants 
(Aychek et al. 2008). Interestingly, both tables identified DARC and CCL19 as up-regulated 
genes. DARC is an atypical chemokine (Duffy Blood Group) and CCL19 is chemokine 
ligand (C-C Motif). Many publications support the notion that DARC and CCL19 are both 
expressed by stromal cells. In fact, DARC is a decoy cytokine receptor that is expressed on 
vascular endothelial cells and is known to trigger senescence in tumor cells 
(Bandyopadhyay et al. 2006; Iiizumi et al. 2007). The chemokine CCL19 is released by 
lymphatic endothelial cells and T-cells of the lymph node and act as ligands of CCR7. It is 
known that CCR7 expression is highly expressed in breast cancer cells and is related to 
lymph node metastasis (Nakata et al. 2008; Müller et al. 2001). Because some of the up- 
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Table 2.3: Top 20 up-regulated genes in DCIS vs. IDC (subgroup-A) 
  
Gene ID DCIS [counts] IDC-A [counts] log2 fold change p value 
CCL21 0.170349073 688.2937044 11.98031451 2.06E-16 
LTB 0.847375119 180.4590634 7.73445512 1.45E-14 
CCL19 8.651999547 1683.222988 7.603977008 1.18E-13 
DARC 1.874469229 363.3545112 7.598751865 8.94E-50 
PLA2G2D 0.602246968 109.0443122 7.500343579 1.17E-12 
CD247 0.900710435 106.9000804 6.890983847 6.12E-20 
CD2 3.399181133 395.1170182 6.860948935 5.41E-28 
IL7R 8.225440724 922.8725355 6.809894609 2.35E-50 
MS4A1 4.190367432 398.2318704 6.570388122 3.03E-05 
CD3E 1.157367137 107.2629222 6.534161067 1.13E-14 
GZMK 2.347138292 207.6398944 6.467037002 1.87E-20 
LCK 2.186226579 193.2745088 6.466064632 1.72E-21 
CSF2RB 4.625420386 362.1313371 6.290784723 1.13E-15 
CCR7 1.858701 144.4863406 6.280494591 1.40E-16 
CD52 16.92475936 1260.471406 6.218684259 1.81E-15 
CD48 6.992472573 516.6267999 6.207175985 1.76E-25 
IL2RG 4.495106588 324.9917898 6.175904136 6.68E-21 
CD3D 5.167625796 366.242134 6.14715236 4.00E-11 
PTPRCAP 2.276762187 147.2180352 6.014827005 1.44E-13 
PTGDS 5.431382056 342.3696934 5.97809184 1.25E-19 
Based on abundant genes above 100 rpm 
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Table 2.4: Top 20 up-regulated genes in DCIS vs. IDC (subgroup-B) 
 
 
 
 
 
 
 
 
 
 
Gene ID DCIS [counts] IDC-B [counts] log2 fold change p value 
DARC 1.871324305 159.4122348 6.412558947 2.01E-05 
SELE 3.865334705 205.1276593 5.729784883 0.000674387 
DSG1 5.183437809 182.7749067 5.140014952 5.13E-11 
IGLL5 41.20435265 1367.589955 5.052695176 0.007256623 
LOC646736 4.864919275 141.8743084 4.866053684 3.62E-09 
SNORA70F 5.980372354 171.3459661 4.840533104 1.12E-08 
LINC00864 4.253391352 114.9093593 4.755738897 7.28E-12 
PLSCR5 7.90720515 203.5293182 4.685924963 4.97E-08 
LOC100144595 12.14756489 309.7768164 4.672490133 1.52E-05 
UGT2B4 8.358162067 212.36979 4.667249012 0.000593047 
PMCHL2 11.76286395 296.0673512 4.653614139 5.53E-21 
CCL19 8.439768349 208.5736633 4.627209789 0.000270716 
LAMB4 14.68078336 357.314458 4.605193434 5.40E-10 
UTS2B 4.464203884 108.1220261 4.598113724 0.000242235 
PGAM1P5 6.813545769 163.0010807 4.580331947 0.00036807 
CDH8 6.08313759 145.0577473 4.575667904 0.000163982 
C9orf153 4.773991355 112.6460356 4.560456776 2.82E-06 
LOC152578 4.981497753 117.3977404 4.558681258 4.58E-15 
KLHL1 4.954127604 116.424215 4.554616316 3.41E-05 
NXPH2 10.76034935 248.7185469 4.53071727 4.83E-05 
Based on abundant genes above 100 rpm 
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regulated genes in IDC seem to be preferentially expressed in stromal cells, there might be 
some stromal contamination in the IDC lesions that we collected. 
In summary, we were able to identify differentially expressed genes that have 
previously been to shown to be involved in DCIS or IDC. In the future, it will be important 
to exclude IDC samples with high stromal contamination in order to avoid false-positive in 
the differentially expressed gene list. In addition, we are planning to analyze the gene 
expression signature from the surrounding stroma, for example to identify differentially 
expressed genes between stroma that is adjacent to DCIS vs. stroma that is adjacent to IDC. 
One hypothesis is that the stroma might be important for determining whether disease 
actually progresses to invasive carcinoma. Overall, it is our hope that we will be able to 
identify biomarkers that might have predictive power over patient outcome.  
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Methods 
 
Tissue collection 
Core needle samples from the Duke SPORE breast tumor bank were shipped on dry 
ice to Cold Spring Harbor Laboratory for processing. These tissue samples were cut into 
multiple 10 µm thick sections, mounted to RNAse free PEN membrane slides (Leica) and 
quickly stained with Toluidine blue (Sigma). For each DCIS patient sample, we isolated 
multiple distinctive DCIS lesions, invasive carcinoma, stromal cells and normal tissue using 
the LMD 7000 laser capture microscope (Leica). Three serial sections were cut from each 
distinctive tissue lesion in order to provide biological replicates for the RNAseq library 
generation. Tissue sections were collected in Prelude Direct lysis buffer (NuGEN). Images of 
each tissue lesion were taken pre- and post-dissection. The histology of each tissue lesion 
was documented and post-analyzed by the pathologist, Dr. Joseph Geradts, at the Duke 
SPORE breast tumor bank. 
 
RNA-Seq library preparation 
Total RNA from dissected individual tissue lesions were converted to double-
stranded cDNA using the SMARTer Ultra Low Input HV system (Clontech). cDNA was 
fragmented using the Covaris LE220 sonicator according to the manufacturer’s instruction 
to yield a target fragment size of 200 bp. About 10 ng of amplified cDNA was used to 
construct Illumina sequencing libraries using the Ovation Ultralow Library System 
(NuGEN). Sequencing was performed on the Illumina HiSeq 2000 instruments.  
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Analyses 
RNAseq samples were mapped to the human genome (hg19), and unique reads were 
annotated against RefSeq (Release 59) gene model as described above. Gene abundances 
were obtained using HTSeq package, and normalized by millions of mapped reads in each 
library (Reads Per Million, RPM).  Genes with less than 10 RPM were removed and for the 
rest, expression values log2-transformed. Hierarchical clustering was then performed based 
on Pearson correlation values, with cluster distances computed using complete linkage.  
For the Principal component analysis, normalized gene abundances were obtained 
from RNAseq samples as previously described, and log2-transformed. PCA was performed, 
and the samples were plotted along the first two principal components (PC1 and PC2). 
Samples were color-coded either by their tissue type (DCIS, normal, IDC or stroma), or the 
patient ID.  
For the subtype classification, normalized gene abundances were obtained from 
RNAseq samples as previously described. A heatmap of genes belonging to the PAM50 set 
of breast cancer subtype markers was generated from log2-transformed gene abundances, 
with hierarchical clustering of both samples (DCIS, IDC and normal) and PAM50 genes 
using Pearson correlation values and complete linkage for cluster distances.  
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Chapter contributions 
Sara Gutiérrez-Ángel assisted with laser-capture microscopy and RNAseq library 
preparation, Dr. Oliver Tam and Prof. Molly Hammel conducted bioinformatics analysis 
and Dr. Joseph Geradts assessed histology of post-cut specimens. 
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Chapter 3: Functional genomics of disseminated and circulating tumor cells 
in a breast cancer mouse model 
 
Breast cancer starts as a local disease, but can spread to distant organs through a 
multi-step process. Malignant cells from the primary tumor enter the blood circulation and 
ultimately metastasize to distant organ sites, such as lung, liver and bone. We have utilized 
a well-established mouse model of breast cancer metastasis to study individual aspects of 
the metastatic cascade. We were able to show that a non-metastatic mouse breast cancer cell 
line was able to metastasize to the lung upon T-cell immune suppression. Exome capture 
sequencing was carried out in order to identify potential neo-antigens that might be 
recognized by these T-cells. 
In addition, we have used these mouse breast cancer cell lines to look at the biology 
of circulating tumor cells (CTCs) in the blood.  For this, we fluorescently tagged tumor cells 
in order to isolate CTCs, metastatic tumor cells in the lung and liver and primary tumor 
cells for gene expression profiling. The goal of this approach was to identify genes that 
contribute towards metastasis formation. We decided to focus on genes that were 
overexpressed in CTCs vs. the primary tumor. From this gene list, we were able to identify 
and functionally characterize Ptpn22 as a metastatic inducer using a pooled in vivo shRNA 
screen. Knock-down studies using shRNAs against Ptpn22 revealed a reduction in overall 
lung metastasis. This is due to a decrease in the number of CTCs in the blood circulation 
upon Ptpn22 knock-down. In vitro assays that mimic the growth and survival of CTCs in the 
blood circulation revealed a higher apoptotic rate upon reduction of Ptpn22 levels. Taken 
together, we were able to identify a novel metastatic regulator that specifically acts on the 
survival of CTCs. 
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Metastatic potential of the 4T1 cell line series 
 
 The 4T1 mouse mammary tumor model consists of five distinct tumor cell lines, 
called 4T1, 66cl4, 168FARN, 4T07 and 67NR. All of these lines have been derived from a 
single spontaneous mammary tumor in a wild-type BALB/c mouse (Dexter et al. 1978; 
Aslakson and Miller 1992; Miller et al. 1983b). The 4T1, 66cl4 and 168FARN cells display an 
epithelial morphology, whereas the 4T07 and 67NR show a more mesenchymal morphology 
(Fig 3.1a). When these cells are orthotopically injected into the mammary gland of syngeneic 
BALB/c mice, they form mammary tumors with similar kinetics. However, their metastatic 
potential differ significantly (Fig 3.1b) (Aslakson and Miller 1992). The 4T1 cell line is the 
most aggressive cell line and readily metastasizes to distant organ sites including lung, liver, 
bone and brain within 3 – 4 weeks. The 66cl4 cell line is weakly metastatic and primarily 
metastasizes to the lung through the lymphatic system (Miller et al. 1983a). The 4T07 cell 
line is able to disseminate from the primary tumor, however is not able to colonize any 
distant organ sites (Miller et al. 1987). The 168FARN cell line metastasizes to the adjacent 
lymph node and the 67NR cell line is non-metastatic. For both 168FARN and 67NR, no 
tumor cells are detectable at distant organ sites (Miller et al. 1986). Interestingly, the 4T1 and 
4T07 cell lines are derived from the same parental cell line called 410.4 (Aslakson and Miller 
1992). The 4T1 cell line is a thioguanine-resistant variant that was selected from the 410.4 cell 
line without mutagen treatment. On the other hand, the 4T07 cell line is a thioguanine-
resistant and ouabain-resistant variant that was treated with mutagen (Miller et al. 1987).  
We wanted to validate the metastatic potential of these five different cell lines in our 
hands. Thus, we injected 2 x 106 cells of each cell line separately into the mammary gland of 
syngeneic BALB/c female mice. After 4 weeks, we harvested the primary tumors, lungs and 
liver and processed them for Hematoxylin and Eosin (H&E) staining. We were able to detect  
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Figure 3.1 Morphology and metastatic potential of 4T1 variants  
(a) Phase-contrast images of the 4T1 variants in vitro. The 4T1, 66cl4 and 168FARN cell lines 
display an epithelial morphology, whereas the 4T07 and 67NR show a more mesenchymal 
morphology. (b) Schematic overview of the differential metastatic potential of the 4T1 
variants. 200,000 cells were injected orthotopically into the mammary gland of BALB/c mice 
and the mice were sacrificed after 4 weeks (5 mice per cell line). For lungs and liver, the 
number of maco-metastases was evaluated based on H&E staining. Lymph node metastasis 
was evaluated based on H&E staining of the brachial lymph node. Blood was drawn and 
cultured in vitro in order to count the number of surviving colonies. 4T1 and 66cl4 cells are 
able to metastasize and colonize distant sites. 4T07 cells are able to disseminate from the 
primary tumor, but are unable to form distant metastases. 168FARN metastasizes to the 
local lymph node. 67NR is non-metastatic. 
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   Metastatic	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micro- and macro-metastases in the lung and liver of animals that were injected with the 
4T1 cell line (Fig 3.2). The 66cl4 mice contained overt lung metastases, but no metastases 
were detected in the liver (Fig 3.2). The 4T07, 168FARN and 67NR did not display any 
metastases in the lung or liver based on H&E stainings. However, the 4T07 liver showed 
extensive sites of hematopoiesis (Fig 3.2), implicating an activation of the immune system 
upon injection of the 4T07 cells.  
It is interesting to note that although 4T07 and 67NR show a more mesechnymal 
phenotype in vitro, which is often correlated to an epithealial-mesenchymal transition (EMT), 
they did not display an metastastic phenotype, when injected into syngeneic BALB/c 
animals. EMT is a process in which epithelial cells loose cell polarity and cell-cell adhesion 
to gain migratory and invasive properties and it is thought that this is a prerequisite for the 
initiation of metastasis (Tsai and Yang 2013). Thus, an EMT phenotype alone might not be 
sufficient for metastasis. However, there is also the possibility that other factors such as the 
immune system might suppress the metastatic phenotype of these cells (Bidwell et al. 2012). 
 
4T07 cells are metastatic upon T-cell immune suppression  
 4T07 cells have no metastatic potential in wild-type BALB/c mice when injected into 
the mammary gland (Aslakson and Miller 1992). In contrast, we observed that injection of 
these cells into immunocompromised nude mice resulted in accelerated primary tumor 
growth that is similar to the primary tumor kinetics of 4T1 cells. Interestingly, we detected 
CTCs and lung metastases when the 4T07 cells are injected into nude mice, but not when 
they are injected into wild-type BALB/c animals (Table 3.1, see method section for isolation 
procedure). Nude mice can not develop mature T lymphocytes (CD4+ and CD8+) (Cordier 
and Haumont 1980). Since 4T07 cells are able to metastasize in an immunosuppressive  
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Figure 3.2 Histological analysis of primary tumor, lung and liver of 4T1, 66cl4 and 4T07 
injected mice   
2 x 106 cells were injected into the mammary gland of mice and primary tumor, lung and 
liver were harvested 4 weeks after injection. 4T1-injected animals displayed metastases in 
lung and liver, whereas 66cl4 injected animals showed only metastases in the lung. The 
4T07-injected animals did not show any metastases in the lung or liver, however the 4T07 
liver showed extensive areas of hematopoiesis. Arrows indicate metastatic areas. All 
primary tumors showed areas of necrosis. 
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Table 3.1: Metastatic profile of 4T07 cells orthotopically injected into Balbc/c or nude 
mice 
 
 
 
 
  
Cell line 
Lung mets 
[# of cells collected 
per mouse] 
Liver mets 
[# of cells collected 
per mouse] 
CTCs 
[# of cells collected 
per mouse] 
Primary tumor growth 
[average time the mice 
reached endstage] 
4T07 Venus 
BALB/c 0 cells  0 cells 0 cells 35 days 
4T07 Venus 
nude 10,000 – 20,000 cells 0 cells 1000 – 2500 cells 22 days 
n = 5 mice per group 
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environment, we hypothesize that these cells might be recognized and targeted by T-cells in 
an immunocompetent setting. In order to analyze this hypothesis we induced T-cell 
depletion in immunocompetent wild-type BALB/c mice by simultaneous anti-CD4 and -
CD8 antibody treatment (intraperitoneal injection of 200 µg of each antibody every 5 days, 
Fig 3.3a). To check for proper T-cell depletion, the spleen of a mouse was isolated after a 
single anti-CD4 and -CD8 antibody injection, and no T-cells were detected by FACS analysis 
(Fig 3.3b). 3 weeks after injection of 4T07 cells and anti-CD4 and -CD8 antibody treatment, 
primary tumors and lungs were isolated. A large effect on primary tumor growth was 
observed between the two treatment groups. Animals with depleted CD4+ and CD8+ T-cells 
showed larger primary tumor growth than the control group, which was injected with PBS 
(Fig 3.3c). Analysis of lung metastases in H&E histological sections indicated an increased 
metastatic potential in T-cell depleted BALB/c mice in comparison to PBS treated control 
mice (Fig 3.3d). No lung metastases were found in any BALB/c control mice, even when the 
primary tumor reached the same size as the CD4/CD8 depleted mice. PBS was used as a 
control since abundant amounts of an isotype control antibody was not available.  
In order to identify 4T07-specific T-antigens, we decided to carry out exome capture 
sequencing of the 4T1 cell lines (67NR, 168FARN, 4TO7, 66cl4 and 4T1). We generated 
exome capture libraries of all lines and identified single nucleotide variants (SNVs). The 
sequencing results revealed many SNVs between the different cell lines (Table 3.2). The cell 
lines 66cl4, 4T07 and 168FARN showed higher numbers of unique SNVs than the 4T1 and 
67NR cell lines. This can be attributed to the fact the 4T1 and 67NR variants have not been 
treated with a mutagen, whereas the other variants were mutagenized during their selection 
process. We were interested in identifying SNVs that were present in the 4T07 cell line, but 
not in the 4T1 line in order to identify potential neo-antigens that might be recognized by T- 
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Figure 3.3 Depletion of CD4+ and CD8+ T-cells accelerates primary tumor growth and 
induces metastasis of 4T07 cells in BALB/c mice 
(a) 4T07 cells are injected into the mammary gland of BALB/c mice and T-cell are depleted 
by simultaneous injection of anti-CD4 and -CD8 antibodies every 5 days. Animals are 
sacrificed after 3 weeks and primary tumor growth und lung metastases are evaluated by 
microscopy and histology. (a) FACS analysis shows depletion of T-cells in the spleen 4 days 
after a single injection of anti-CD4 and -CD8 antibodies. (c) Differential tumor growth 
between animals that were treated with anti-CD4 and -CD8 treatment and with PBS only. 
(d) Lungs of animals treated with anti-CD4 and -CD8 displayed large metastatic nodules 
under the microscope. H&E stainings revealed multiple micro and macro-metastases. 
Arrow indicates metastatic area. 
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Table 3.2: Exome capture sequencing of the 4T1 cell lines revealed many single 
nucleotide variants (SNVs) 
 
  
Sample 
Relative 
metastatic 
potential 
EMS 
mutagenized 
Total SNVs 
called 
SNVs unique to 
this line 
4T1 high no 79229 65 
4T07 low yes 75350 781 
66CL14 medium yes 77105 601 
168FARN very low yes 82357 746 
67NR none no 111694 248 
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cells in the 4T07 system. For this, we overlapped these unique SNVs with our in vitro 
transcriptome data in order to identify SNVs in the 4T07 cell line that were highly expressed 
in the 4T07 variant vs. the 4T1 line (Table 3.3). One of the top hits was P2ry14, a G-protein 
coupled receptor. This receptor specifically responds to UDP-glucose and related sugar 
nucleotides (Abbracchio et al. 2003). In addition, there are algorithms available that will 
predict if antigenic peptides can bind to the major histocompatibility complex (MHC) class I 
molecules (Newell and Davis 2014). It will be interesting to see if any of the mutated 
peptides can be incorporated into the MHC groove for T-cell recognition.  
In summary, we were able to detect accelerated primary tumor growth and overt 
lung metastases of 4T07 cells upon T-cell depletion in BALB/c mice. It would be advisable 
to repeat this experiment with an isotype control antibody, since there might be an increase 
in inflammation due to antibody treatment. The exome capture sequencing of 4T07 revealed 
many unique SNVs that are highly expressed in 4T07, compared to the 4T1 variant. We 
think that since both 4T07 and 4T1 cells were isolated from the same precursor variant, a 
direct comparison between both cell lines is useful. In order to see if these candidate gene 
products could display neo-antigens for T-cell recognition, a method called SEREX 
(serological analysis of recombinant tumor cDNA expression libraries) could be employed 
(Zhou et al. 2012). In this method, cDNA libraries are extracted from 4T07 primary tumors 
in order to immune-screen gene products recognized by T-cells. These clones are then 
directly sequenced and their identity can be determined. In addition, T-cell receptor 
sequencing might provide another alternative in order to identify endogenous pairs of T-cell 
receptor sequences from 4T07 injected mice.  
Furthermore, in order to see whether 4T07 cells are able to circumvent the T-cell 
immune system in BALB/c mice by adaption, serial injections of 4T07 cells into BALB/c 
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mice could be performed. Doing RNAseq analysis of the cells after serial culturing and 
comparing them to the parental 4T07 cells, we might be able to narrow down potential T-
cell antigens. 
4T07 and 4T1 cells are derived from the same precursor cell line, whereas 4T07 cells 
were mutagenized with EMS, but not 4T1 cells. Thus, an EMS induced mutation in the 4T07 
cell line might act as a neo-antigen for T-cell recognition. Given that this mutation was 
induced by EMS and not during tumor progression, this neoantigen might not be relevant 
for human breast cancer progression. However, the mechanism of how these neoantigen 
specific T-cells eliminate metastatic tumor cells might provide insight into designing 
effective treatments to induce immune responses against tumor cells.  
 
Transcriptional profiling of primary tumor cells, CTCs and metastatic cells 
 We utilized the 4T1 mouse breast cancer cell line series, which consists of five 
distinct tumor cell lines (4T1, 66cl4, 4T07, 168FARN and 67NR). We generated gene 
expression profiles (RNAseq libraries) from these cell lines in vitro and also in vivo, by 
injecting them orthotopically into mice to isolate primary tumor cells, CTCs and metastatic 
tumors cells in lung and liver. We wanted to compare the gene expression profiles to each 
other in order to identify genes that are important for the metastatic process. We 
hypothesize that each of the defined metastatic potential displayed by these cell lines are 
partially due to alterations of gene expression in the various compartments (primary tumor, 
CTCs and lung/liver metastases).  
To generate the gene expression profiles, we orthotopically injected fluorescently 
labeled (Venus+) cells from each cell line separately into the mammary gland of nude mice. 
We decided to use immunocompromised mice since we detected engraftment issues with  
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Table 3.3: SNVs that were uniquely present and highly expressed in 4T07 (sorted based 
on log2 fold change expression 4T07/4T1) 
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the 4T1 cell line series that carried various fluorophores such as tdTomato and Venus. The 
primary tumor growth rate and the metastatic potential were greatly reduced when these 
foreign antigens were incorporated into these cell lines and injected into immunocompetent 
BALB/c mice. At 4 weeks post-injection, primary tumor cells, CTCs from the blood and 
metastatic tumor cells from the lung and liver were isolated for gene expression profiling. 
In order to isolate pure populations of tumor cells from the primary site, lung and 
liver, we enzymatically digested these tissues into single cells with collagenase and 
hyaluronidase and then sorted them based on fluorescence using FACS (Venus+ cells, Fig. 
3.4b). Similarly, we have developed a sensitive approach to isolate CTCs from the peripheral 
blood (Fig 3.4a). After whole blood collection by terminal cardiac puncture, erythrocytes 
were removed by red blood cell lysis and then CD45+ leukocytes and Ter119+ erythrocytes 
were immunomagentically depleted from the blood. After this, CTCs were isolated using 
FACS based on fluorescence (Venus+ cells). All of these cell populations were collected in 
lysis buffer for gene expression profiling. For all cell lines, primary tumor cells were 
collected. In addition, lung metastatic cells were collected from the 4T1, 66cl4 and 4T07 cell 
line and liver metastatic cells were collected from the 4T1 line. We were able to collect CTCs 
from the 4T1, 66cl4 and 4T07 cell lines (Table 3.4).  
RNAseq libraries were generated from total RNA using the Nugen Ovation RNA-
Seq System II. The libraries were sequenced on the Illumina platform (single-end, 50 cycles). 
Sequencing reads were mapped to the mm9 mouse genome using TopHat and differential 
expression was assessed using Cufflinks/Cuffdiff (Trapnell et al. 2010; 2009). The 
percentage of unique mappers to the genome was around 80% to 90% of total reads. For 
some lung samples, this was around 70%. Pearson correlation between biological replicates 
for each condition was above 0.85 for all samples, except for some lung samples (Fig. 3.5a).  
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Figure 3.4 Isolation procedure for CTCs, primary and metastatic tumor cells  
(a) Whole blood is isolated from mice through terminal cardiac puncture. After red blood 
cell (RBC) lysis, whole blood is stained with anti-CD45 (leukocytes) and anti-Ter119 
(erythrocytes). The cells are immunomagnetically delpleted and Venus+ cells are isolated by 
FACS. (b) Primary tumor, lung and liver are harvested from mice and then enzymatically 
digested with collagenase and hyaluronidase into single cells. Venus+ cells are isolated by 
FACS. 	  
 
 
 
 
 
a 
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Principle component analysis (PCA) on the RNAseq data revealed higher separation 
between each of the cell lines than separation between each of the replicates (not shown). 
Hierarchical clustering of the RNAseq data revealed a tropism based on the tissue origin 
(Fig 3.5b). All of the primary tumor cells clustered together and so did the CTCs and lung 
metastatic cells. Interestingly, the CTCs clustered closer to the primary tumors than to the 
lung metastatic cells.  
In summary, we were able to obtain high-quality RNAseq libraries, even from 
samples with very low input RNA. The Pearson correlation between biological replicates 
were very high for most samples, except for some lung samples. This might be due to the 
harsh isolation procedure, in which we enzymatically digest the lung tissue into single cells. 
These lung samples also have a low percentage of unique mappers. Because of this, we 
decided to primarily focus on the analysis of the primary tumors and CTCs.  
Another technical limitation is the sorting of these cells based on fluorescence. 
Because it is nearly impossible to get a pure population from the FACS sorts, there might be 
some contamination of non-tumorigenic cells. However, we can estimate that this 
percentage is less than 10%, since we were able to get over 90% pure populations from 
FACS sorts when we analyzed the post-sorted cell populations.  
Because the tumor cells were tagged with a fluorophore, we were able to isolate the 
whole CTC population regardless of surface makers. The FDA-approved CellSearch system 
uses a mix of cytokeratins and EpCAM to identify and isolate CTCs (Müller et al. 2012). 
Since it is known that many tumor cells undergo EMT, in which they down-regulate 
epithelial makers, this system might not be able to isolate all CTCs in a given sample (Tsai 
and Yang 2013). A recent study showed that many CTCs from human cancer patients do 
show expression of mesenchymal markers (Yu et al. 2013). Fortunately, we are able to  
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Table 3.4 Number of FACS sorted cells collected for each of the 4T1 cell line 
 
 
 
 
 
 
 
  
Cell line 
Primary tumor 
[# of cells collected 
per mouse] 
Lung mets 
[# of cells collected 
per mouse] 
Liver mets 
[# of cells collected 
per mouse] 
CTCs 
[# of cells collected 
per mouse] 
67NR 
Venus 
++ 
200,000 cells  − − − 
168FARN 
Venus 
++ 
200,000 cells − − − 
4T07 
Venus 
++ 
200,000 cells 
++ 
10,000 – 20,000 cells − 
+ 
1000 – 2500 cells 
66cl4 
Venus 
++ 
200,000 cells 
++ 
10,000 cells − 
+/− 
No cells – 30 cells 
4T1 
Venus 
++ 
200,000 cells 
++ 
20,000 cells 
+ 
50 – 250 cells 
++ 
8000 – 20,000 cells 
n = 2 mice per group 
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Figure 3.5 Statistical analysis and clustering of RNAseq data   
(a) Pearson correlation between biological replicates for each of the cell line and the tissue 
that it was isolated from (b) Hierarchical clustering of RNAseq libraries. Columns represent 
averages of two mice. 
  
b a 
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circumvent this by using a fluorophore and only using a negative depletion, in which we 
removed leukocytes based on CD45 and erythrocytes based on Ter119.  
 
Ptpn22 is a novel metastatic inducer 
We wanted to identify potential metastatic regulators and thus looked for 
differentially expressed genes between the CTC population and the primary tumor. This 
was done in the case of the 4T1 and 4T07 cell lines. 12 genes were identified that were 
significantly overexpressed in the CTCs vs. primary tumor in both the 4T1 and 4T07 cell 
lines (above 4 fold and abundant > 10 FPKM, Fig. 3.6a,b). Some of these genes have been 
implicated with breast cancer and metastasis before. Aquaporin 1 (AQP1) is a water channel 
protein, whose expression has been found to correlate with aggressive basal-like breast 
carcinomas (Otterbach et al. 2010). Synuclein gamma (Sncg) is involved in perineural 
invasion and distant metastasis in a pancreatic cancer mouse model (Hibi et al. 2009). In 
addition, SNCG expression can be used as a marker for breast cancer prognosis, especially 
for stage III and IV breast cancer (Wu et al. 2007). G protein-coupled receptor kinase 4 
(GRK4) has been identified to activate the MAPK signaling pathway in breast cancer cells 
(Matsubayashi et al. 2008). Because many of these candidate genes have been implicated 
with cancer progression and metastasis, we decided to screen these 12 genes in a pooled 
fashion.  
In order to check the feasibility of an in vivo shRNA screen with these 12 genes, we 
decided to check the number of clones that engraft in the primary tumor and lung using a 
high complexity barcode library. This lentiviral barcode library was infected into 4T1 cells 
and were injected orthotopically into nude mice. After 4 weeks, primary tumor and lung 
were isolated and the overall number of barcodes were determined. On average, the  
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Figure 3.6 Overview of genes that are overexpressed in CTCs vs. primary tumor in 4T1 
and 4T07 
(a) Overlap of overexpressed genes between CTCs and primary tumor in both 4T1 and 4T07. 
(b) Heatmap of the 12 overexpressed genes. 
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primary tumor contained around ~4700 barcodes and the lung contained around ~1550 
barcodes. Because we wanted to have a ~100x fold representation of our shRNAs in the lung, 
we decided to use a maximum of 18 shRNAs per pool. Because of the unequal engraftment 
of some of the clones in the primary tumor and lung, we decided to use 6 mice per pool (see 
Chapter 4 for barcode representation of 4T1 cells). 
We decided to screen these 12 candidate genes in an in vivo metastasis depletion 
assay (Fig 3.7a). For this, we infected 4T1 cells with shRNA pools (18 shRNAs per pool, 3-4 
shRNAs per gene) and injected these cells orthotopically into the mammary gland of nude 
mice. After 4 weeks, we isolated the primary tumor and lung and subsequently sequenced 
shRNA representation. We scored shRNAs that were significantly depleted in the lung 
compared to the primary tumor using the software EdgeR (Robinson et al. 2010), since this 
would confirm that the candidate gene is necessary for metastasis. Ptpn22 was revealed as 
one of the top hits in this screen for metastatic inducers (Table 3.5).  
Ptpn22 is a protein tyrosine phosphatase, which is expressed primarily in lymphoid 
tissue (Cohen et al. 1999). It has been implicated in autoimmunity susceptibility, response to 
injection and systemic inflammation (Brownlie et al. 2012). Interestingly, the 2012 TCGA 
Breast Cancer report highlighted Ptpn22 as one of the novel significantly mutated genes in 
their data set (Cancer Genome Atlas Network 2012). 
Follow-up studies were performed with Ptpn22. Individual shRNAs against Ptpn22 
and a control shRNA against Renilla were infected into 4T1 cells and each cell line was 
orthotopically injected into nude mice (Fig. 3.7b). Lung metastasis was evaluated after 4 
weeks and we detected a reduction in lung metastases upon Ptpn22 knock-down (Fig 3.8a,b). 
Because of the promising results with Ptpn22, we decided to look at its potential mode of 
action during metastasis.  
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Figure 3.7 Schematic of pooled depletion metastasis screen and one-by-one validation 
(a) Several shRNAs targeting multiple genes are pooled and infected into 4T1 cells. These 
cells are orthotopically injected into mice and the primary tumor and lung are harvested 
after 4 weeks. Depletion of specific shRNAs in the lung compared to the primary tumor 
confirms that this candidate gene is necessary for the metastatic process (b) A single shRNA 
targets a gene and is infected into 4T1 cells. These cells are used for in vitro experiments such 
as invasion assays and for in vivo assays, such as orthotopic injections.  
  
a      b 
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Table 3.5: Depleted shRNAs from the in vivo metastasis screen   
 
 
 
 
 
 
  
depleted 
shRNAs 
log2 
fold change p value FDR 
Ptpn22_4 4.74 0.0011 0.0087 
Ptpn22_1 2.59 0.0131 0.0474 
Psg28_2 3.47 0.0037 0.0184 
Psg28_3 3.04 0.0116 0.0474 
Tppp_1 3.79 0.0043 0.0184 
Sfi1_2 3.36 0.0056 0.0192 
Ctrl (neutral) 1.14 0.2895 0.3990 
Ctrl (neutral) 0.34 0.7463 0.9185 
6 biological replicates per pool 
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In order to study the effects of Ptpn22 on metastasis formation, we infected 4T1 cells 
with Ptpn22 shRNAs and a control shRNA (Fig 3.7b) and carried out various in vitro and in 
vivo assays. We did not detect any changes in proliferation in vitro, as calculated by total cell 
number, and in vivo, as calculated by primary tumor growth, upon Ptpn22 knock-down in 
4T1 cells (Fig 3.9a,b). In addition, there was no change in invasion in in vitro in a matrigel 
based invasion assay (Fig 3.9c). We used an shRNA against Sncg as a positive control (Jia et 
al. 1999). Because of these results, we were certain that there is likely no effect on 
proliferation and invasion upon Ptpn22 knockdown in 4T1 cells. We next drew our attention 
to CTCs and wanted to see if there is a change in numbers of CTCs. Interestingly, we were 
able to see a reduction in CTC numbers after orthotopic injection of 4T1 cells with Ptpn22 
knock-down (Fig 3.9d). We used the same CTC isolation technique as for the gene 
expression profiling (Fig 3.4a). Because of the fact, that there was no change in invasion in 
vitro, but a change in the overall number of CTC counts in the blood, we hypothesized that 
CTC survival might be affected upon Ptpn22 knock-down.  
We decided to use an in vitro system that mimics CTC survival, in which we can 
grow 4T1 cells in an anchorage-independent fashion on ultra-low attachments plates. In 
addition we used serum starvation to induce stress on these cells (Fig 3.10a). In these 
settings, we detected an increase of Ptpn22 expression in 4T1 cells (Fig 3.10b). Interestingly, 
there was a higher rate of apoptosis upon Ptpn22 knock-down in these cells compared to the 
control shRNA, as measured by an ELISA for mono- and oligonucleosomes in the 
cytoplasma (Fig 3.10c). This was also confirmed by looking at the gene expression signature 
(RNAseq) of these cells (not shown). Pathway analysis confirmed an enrichment of genes in 
“apoptosis” and “cell death” pathways and a reduction of genes in the “cell survival”  
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Figure 3.8 Ptpn22 knock-down reduced lung metastasis 
(a) 4T1 cells infected with an shRNA against Ptpn22 or a control shRNA (Renilla) were each 
orthotopically injected into nude mice and lungs were harvested after 4 weeks. Metastatic 
lung burden was measured by H&E staining. (b) Quantification of the metastatic lung 
burden from (a). The graph represents box plots.  
  
b a 
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Figure 3.9 Ptpn22 knock-down reduced the number of CTCs, but does not affect 
proliferation and invasion 
4T1 cells infected with an shRNA against Ptpn22 or a control shRNA (Renilla) were used for 
the following experiments. (a) No change in proliferation in vitro upon Pptn22 knock-down 
(b) No change in primary tumor growth upon Ptpn22 knock-down. (c) Matrigel-based 
invasion assays revealed no change in invasion upon Ptpn22 knock-down compared to the 
positive Sncg control. (d) 4T1 cells were orthotopically injected into nude mice and CTCs 
were harvested after 4 weeks. There was a reduction on the number of CTCs upon Ptpn22 
knock-down. The graph represents box plots. 	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pathway. Thus, we think that overexpression of Ptpn22 in CTCs might protect these cells 
from stress-induced apoptosis (Fig 3.11). 
In summary, we were able to show that Ptpn22 is overexpressed in the CTCs vs. the 
primary tumor when 4T1 or 4T07 cells are injected orthotopically into mice. The mode of 
action of Ptpn22 is likely on the survival of CTCs since there was no change in proliferation 
and invasion upon knock-down of Ptpn22 in 4T1 cells. Because we detected the change in 
CTC numbers, we wanted to establish an in vitro system that mimics the survival of CTCs in 
an anchorage-independent and stress inducing condition. Using this assay, we saw an 
increase in apoptosis upon knock-down of Ptpn22 in 4T1 cells, which then resulted in the 
decreased incidence of metastasis in the lung. Since Ptpn22 is a phosphatase, it will be 
interesting to detect specific substrates that might play a role in this mechanism. There are 
several phosphor-receptor tyrosine kinase and protein arrays that allow a semi high-
throughput analysis of this. 
The exact biological mechanism of how Ptpn22 might be pro-survival for the CTC 
population in the blood circulation is not known. Akt possesses pro-survival activities that 
can counteract apoptosis and thus it might be interesting to check the Akt phosphorylation 
levels with and without knock-down of Ptpn22 (Benbrook and Masamha 2011). In addition, 
it will be very important to validate the mode of action of Ptpn22 on lung metastasis in 
human cell lines such as the claudin-low/basal MDA-MB-231 and MDA-MB-436 cell lines. 
Likewise, it will be interesting to see if we could increase the incidence of lung metastasis by 
over-expressing Ptpn22 such as in the 4T07 cell line or in the previously mentioned human 
cell lines.  
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Figure 3.10 Ptpn22 knock-down increased rate of apoptosis in vitro 
(a) 4T1 cells grow in organoids on ultra-low attachment plates under normal conditions 
(10% FBS) and under serum starvation (0.1% FBS) mimicking CTC survival (b) 4T1 cells 
display an up-regulation of Ptpn22 when these cells are grown on ultra-low attachment 
plates and serum starved (c) Under these conditions, there is an increase in apoptosis upon 
Ptpn22 knock-down (measured by ELISA for mono- and oligonucleosomes in the 
cytoplasm) 
 	  
 
 
 
 
  b              c 
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Figure 3.11 Mechanistic effect of Ptpn22 on metastasis 
Knock-down of Ptpn22 in 4T1 cells does not affect proliferation and invasion, but results in 
a reduction on the number of CTCs in the blood stream and a higher apoptotic rate when 
these cells are subjected to stress. This results in an overall reduction of metastasis to the 
lung.  
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Methods 
 
Cell culture 
The mouse mammary tumor cell line 4T1 was purchased from ATCC and the 66cl4, 
4T07, 168FARN and 67NR cell lines were a kind gift from Fred Miller. These cell lines were 
cultured in DMEM high glucose (Life Technologies) supplemented with 5% fetal bovine 
serum (Thermo Scientific), 5% fetal calf serum (Thermo Scientific), non-essential amino acids 
(Life Technologies) and penicillin streptomycin (Life Technologies). 
 
Virus production 
All retroviral vectors were packaged using Platinum-A packaging cells. The 
lentiviral barcode library was packaged using 293-FT lentivirus packaging cells. 
 
Animal studies 
All mouse experiments were approved by the Cold Spring Harbor Animal Care and 
Use Committee. All orthotopic injections were performed using 2 x 105 mouse mammary 
tumor cells resuspended in 20 ul of a 1:1 mix of PBS and growth factor reduced Matrigel 
(BD Biosciences). Cells were injected into mammary gland #4 of 8 week-old female nude or 
BALB/c mice (JAX). Tumor, lung and blood were harvested from mice for further 
processing. Primary tumor volume was measured using the formula V = 1/2(LxW2), where 
L is length and W is width of the primary tumor. 
 
CD4+ and CD8+ depletion 
 Anti-CD4 as well as anti-CD8 antibodies were produced by the CSHL Antibody 
Core facility using the following hybridome lines: GK1.5 for CD4+ T cell depletion, which is 
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an IgG2b-producing rat T cell hybridoma line (Dialynas et al. 1983) and 53-6.72 for CD8+ T 
cell depletion, which is an IgG2a-producing rat hybridoma that reacts with both the Lyt2.1 
and Lyt2.2 alleles (Ledbetter and Herzenberg 1979). 
 BALB/c animals were intraperitoneally injected with 200 µg of each antibody every 
5 days. PBS was used as a negative control. The spleen of a BALB/c mouse treated with 
anti-CD4 and anti-CD8 antibodies was isolated and mashed on a 60 µm cell strainer. Single 
cells were centrifuged and resuspended in PBS before staining with CD4-Alexa648 (BD 
Biosciences) and CD8-FITC (Miltenyi Biotec) antibodies. 
 
Quantification of lung metastatic burden 
The lung metastatic burden was evaluated in five-micron sections stained with a 
standard H&E protocol. Quantification was performed using ImageJ Software (NIH). The 
total lung area and metastatic area was determined by tracing the individual regions by 
hand. The relative metastatic area was then calculated.  
 
Isolation of blood, primary tumor and lung and liver metastatic cells 
 Tumor, lung and liver were enzymatically digested into single cells using a 
collagenase and hyaluronidase buffer (Stemcell) and then sorted based on fluorescence 
using the FACS AriaII (BD Biosciences). Whole blood was collected by terminal cardiac 
puncture, erythrocytes were removed by red blood cell lysis (ACK Buffer, Sigma) and then 
CD45+ leukocytes and Ter119+ erythrocytes (BD Biosciences) were immunomagentically 
depleted from the blood using LS columns (Miltenyi Biotec). After this, CTCs were isolated 
using FACS based on fluorescence using the FACS AriaII (BD Biosciences).  
 
	   70 
Complexity analysis  
Genomic DNA was isolated using phenol chloroform extraction. The barcodes of the 
lentiviral library were amplified using a one-step PCR protocol. For each sample, 96 
individual PCR reactions of 500 ng of genomic DNA were carried out using Phusion 
(Thermo Scientific). The PCR was carried out for 33 cycles. PCR products were purified 
using the PCR purification kit (Qiagen). PCR products were size selected on an agarose gel, 
and then sequenced on the Illumina GaIIx sequencer generating 36 nt single-end (SE) reads. 
The complexity library was analyzed in collaboration with Dr. Simon Knott.  
 
shRNA analysis 
Genomic DNA was isolated using phenol chloroform extraction. The shRNAs were 
amplified using two-step PCR protocol. The first PCR was carried out for 25 cycles. PCR 
products were purified using the PCR purification kit (Qiagen). The second PCR was 
performed using 500 ng of PCR product from the first PCR. The second PCR was carried out 
for 25 cycles and PCR products were again purified using the PCR purification kit (Qiagen). 
PCR products were size selected on an agarose gel and sequenced on the Illumina GaIIx 
sequencer generating 36 nt single-end (SE) reads. shRNA depletion (fold change between 
tumor to lung) was calculated using EdgeR with a FDR threshold of <0.05. 
 
RNA-Seq library preparation 
Total RNA was purified and DNAse treated using the Qiagen RNeasy Mini Kit. 
RNA integrity (RNA Integrity score > 9) and quantity was measured on an Agilent 
Bioanalyzer (RNA Nano kit). The NuGEN Ovation RNA-Seq V2 protocol was carried out on 
100 ng of total RNA. cDNA was fragmented using a Covaris sonicator according to the 
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manufacturer’s instruction to yield a target fragment size of 300 bp. The fragmented cDNA 
was subsequently processed through end-repair, A-tailing and adapter ligation using our 
in-house one-shot low-input protocol. A minimal PCR amplification was followed using 
Phusion (Thermo Scientific) for 16 cycles. Each sample was sequenced on the Illumina GaIIx 
sequencer generating 50 nt single-end (SE) reads. Sequencing reads were mapped to the 
mm9 mouse genome using TopHat and differential expression was assessed using 
Cufflinks/Cuffdiff. 
 
Exome capture library preparation 
 Genomic DNA was purified using phenol-chloroform extraction. Then, the genomic 
DNA was fragmented using a Covaris sonicator according to the manufacturer’s instruction 
to yield a target fragment size of 300 bp. The fragmented cDNA was subsequently processed 
through end-repair, A-tailing and adapter ligation using our in-house one-shot low-input 
protocol. A minimal PCR amplification was followed using Phusion (Thermo Scientific) for 
16 cycles. Then, the SeqCap EZ Mouse exome capture (Roche NimbleGen) was used 
according to the manufacturer’s instruction and then sequenced on the Illumina HiSeq 
sequencer generating 76 nt single-end (SE) reads. The Exome-capture sequencing was 
analyzed in collaboration with Prof. Molly Hammell (CSHL). 
 
qRT-PCR 
Total RNA was purified and DNAse treated using the RNeasy Mini Kit (Qiagen). 
Synthesis of cDNA was performed using SuperScript III Reverse Transcriptase (Sigma). 
Quantitative PCR analysis was performed on the Eppendorf Mastercycler ep realplex. All 
signals were quantified using the ΔCt method and were normalized to the levels of Gapdh. 
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Proliferation rates 
 Proliferation assays were performed by counting viable cells over 72 hours. 
 
Invasion Assay 
Invasion assays were done using BioCoat Matrigel invasion chambers (BD 
Biosciences). 2 x 105 4T1 cells were plated per well and FBS was used as a chemoattractant. 
After 18 hours, the invaded cells were stained with 5 µM SYTO 60 (Life Technologies). 
Chambers were scanned using the Odyssey system (Licor). 
 
Apoptosis Assay  
 The Cell Death Detection ELISA (Roche) was carried out in duplicates according to 
the manufacturer’s instructions.  
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   74 
Chapter 4: A model of tumor heterogeneity reveals vascular mimicry as a 
driver of metastasis  
 
Metastasis requires that primary tumor cells evolve the capacity to intravasate into 
the lymphatic or cardiovascular systems, extravasate into a target organ, and colonize 
secondary sites that are physiologically distinct from that of the primary (Nguyen et al. 
2009; Vanharanta and Massagué 2013). We have developed a mouse model to probe the role 
of breast tumor heterogeneity in multiple stages of disease, from primary tumor growth to 
the establishment of metastases.  We found that distinct clones display specialization, for 
example dominating the primary tumor, contributing to metastatic populations, or showing 
tropism for entering the lymphatic or vasculature systems. We correlated these stable 
properties to distinct gene expression profiles. Those clones that efficiently entered the 
vasculature expressed two secreted proteins, Serpine2 and Slpi, that were necessary and 
sufficient to program these cells for vascular mimicry. We hypothesize that vascular 
mimicry drives the ability of some breast tumor cells to contribute to distant metastases 
while simultaneously satisfying a critical need of the primary tumor to be fed by the 
vasculature. Enforced expression of SERPINE2 and SLPI in human breast cancer cell lines 
also enabled vascular mimicry, and SERPINE2 and SLPI were overexpressed preferentially 
in human patients that had metastatic relapse.  Thus, these two secreted proteins, and the 
phenotype they promote, may be broadly relevant as drivers of metastatic progression in 
human cancer. 
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4T1 as a tumor heterogeneity model  
Tumor heterogeneity has been posited as a significant contributor to the failure of 
cancer therapy (Meacham and Morrison 2013; Ding et al. 2012; Mullighan et al. 2008; Lohr et 
al. 2014). Two models have been proposed to explain the heterogeneity in genotype and 
phenotype that is observed within human cancers. The so-called cancer stem cell model 
purports that a fraction of cells within a cancer have high tumor forming potential (Beck and 
Blanpain 2013). These fuel the production of bulk tumor cells that are more differentiated 
and thus less likely to engraft in transplantation experiments or to contribute to therapy 
resistance or metastasis. The clonal evolution model invokes progressive Darwinian 
selection of genetically distinct clones with diverse properties, for example resistance to 
therapy, predisposition for dissemination to secondary sites, and the ability to produce 
metastases (Greaves and Maley 2012). While it is nearly certain that human tumors contain 
populations of cells that are phenotypically and genetically distinct, neither of the two most 
widely considered models likely captures fully the mechanisms that lead to heterogeneity or 
its consequences for human disease (Shackleton et al. 2009). For example, discrete cell 
populations in human tumors can act symbiotically, with one secreting growth factors on 
which the other depends (Neiva et al. 2014; Grivennikov et al. 2009).  Moreover, tumors and 
cancer-associated stromal populations can act together to promote tumor progression and 
therapy resistance (Orimo et al. 2005; Olive et al. 2009). Thus both the mechanisms that 
generate tumor heterogeneity and its impacts on cancer therapy are likely more complex 
and subtle than is generally envisaged. 
To date, the most detailed studies of tumor heterogeneity have been retrospective 
(Mullighan et al. 2008; Lohr et al. 2014; Ding et al. 2010; Navin et al. 2011). For example, 
single cell analyses of human breast tumors have illustrated evolutionary paths of genetic 
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diversification (Navin et al. 2011). In such cases, genetic variation could not be associated 
with differences in the behavior and capabilities of clonal populations and their specific 
contributions to disease. We, therefore, wished to complement such studies by creating an 
experimental model of tumor heterogeneity. Our goal was to enable correlation between 
variations in genotype and gene expression with cellular behaviors that contribute to tumor 
development and metastatic progression. 
Identifying the factors required to overcome each step of the metastatic process has 
been difficult, as comparative genomic studies have been performed mainly with cells from 
the primary and secondary lesions, preventing stratification of the requirements for 
intravasation vs. extravasation (Bos et al. 2009; Minn et al. 2005). One of the most widely 
applied models used to study metastasis is transplantation of the 4T1 cell line into the 
mammary fat pad of mice (Dexter et al. 1978). The 4T1 cell line can be engrafted into 
syngeneic or immunocompromised recipients. Orthotopic transplantation into the 
mammary fat pad leads both to the development of primary tumors and to outgrowth of 
metastases in lymph nodes and secondary organ sites that are accessible via the vascular 
system. Here, we wished to apply this model to connect heterogeneity with metastasis, 
through the tracking, via next generation sequencing (NGS), of individual molecularly 
barcoded 4T1 clones throughout the various stages of metastatic disease progression.  Such 
a system allows individual cells to be assessed for their ability to intravasate and extravasate, 
which, in turn, should allow the factors driving each step to be ascertained. In addition, we 
sought to determine whether each cell within the 4T1 population had equivalent properties 
or whether certain subsets of cells might display stable differences in behavior that could be 
studied in clonal populations.  
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Clonal analysis of 4T1 transplantation 
To address this question, we marked individual cells with a molecular barcode via 
lentiviral infection (Fig. 4.1a and 4.2a). We drew from a complex mixture, five different 
cohorts of 100,000 cells each and introduced these into immunocompromised recipients. 
These were chosen because the barcode library encodes mCherry and hygromycin 
resistance, and we wished to avoid selective pressures imposed by immune rejection based 
upon foreign antigens. After 24 days, primary tumors, brachial lymph nodes, blood, lungs, 
livers, and brains were collected, and the barcode populations within each tissue were 
quantified via next generation sequencing (NGS). Though each engrafted population was 
distinct, there was a set of clones (~1,400) that was present in all samples.  We asked 
whether these clones showed consistent behavior across all 5 experiments.   
An analysis of the distributions of clone abundances across tissues indicated that 
only a subset of engrafted cells were able to intravasate into the cardiovascular and 
lymphatic systems, and an even smaller set were able to extravasate into the lung, brain and 
liver (Fig. 4.3a). A two-dimensional clustering of the clone distributions across organs 
resulted in all tumor, blood and lymph-node samples forming separate groups (Fig. 4.1b). 
Although the blood-born metastases samples formed one large meta-cluster, individual 
samples failed to fully group together based on their organ of origin. 
Two conclusions were drawn from this analysis. First, clone abundance within the 
primary tumor did not correlate with abundance in CTCs or secondary lesions (Fig. 4.3b). 
Second, distinct groups of clones contributed to lymph node and blood-born metastases. 
Highly significant overlap existed between abundant clones in the blood-born metastases, 
and between these and CTCs (p-value < 0.001). However, no significant overlap was 
observed when comparing these sets to the abundant clones in the lymph node (Fig. 4.3c).  
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Figure 4.1. Clonal analysis of 4T1 transplantation by molecular barcoding 
(a) Retroviral barcoding strategy for identifying clonal populations within the 4T1 cell line. 
(b) Relative proportions of clones that engrafted in all animals in the lymph-node (LN), lung, 
liver, brain and blood.  Each column represents an independent experiment.  Shown are the 
~1400 clones that successfully engrafted in all animals.  
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Figure 4.2: Overview of vector plasmids 
(a) Schematic of the retroviral barcode vector. b. Schematic of the lentiviral barcode vector. 
(c) Schematic of the retroviral shRNA vector used for single gene knockdown. (d) Schematic 
of the tandem retroviral shRNA vector used for double gene knockdown. (e) Schematic of 
the retroviral cDNA vector used for gene overexpression.  
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Figure 4.3: Clonal abundances in the primary tumor and secondary sites after 4T1 
transplantation 
(a) Distribution of clone abundances at the primary tumor and secondary sites for the 4T1 
clones that engrafted and contributed to tumor formation in all five animals upon 
orthotopic injection. (b) Overlap of abundant clones in the primary tumor, lymph-node (LN), 
blood and in all blood born metastases (lung, liver and brain).  (c) Overlap of the abundant 
clones in the LN, liver, lung and brain.  
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 These studies implied that clonal populations within the 4T1 line have acquired 
stable differences that enable them to contribute to different aspects of disease progression. 
 
Focused analysis of a subset of 4T1 clones 
In order to gain further insight into these phenomena, using single cell FACS sorting, 
we established clonal lines from 4T1 cells that had been infected with a lentiviral barcode 
library (Fig. 4.2b and 4.5a). Twenty-three lines were chosen that stratified the various 
growth rates and morphologies observed during cell line establishment (hereon referred to 
as 4T1-A through W, Fig. 4.4). After minimal propagation, these lines were pooled in equal 
amounts and orthotopically injected into mice. In addition, the pool was propagated in vitro. 
After 14 days, primary tumors were removed from one cohort of mice and aliquots of the in 
vitro samples collected. After 24-days, a second set of in vitro aliquots were acquired and the 
primary tumors, brachial lymph nodes, blood, lungs, livers and brains were extracted from 
the remaining animals. The abundance of each clone in each sample was determined by 
NGS. 
Figure 4.5b depicts the clonal composition of each primary tumor and in vitro pool 
after 14 and 24 days.  A comparison of samples extracted at 14 days shows high 
concordance between the in vitro samples and the primary tumor clone compositions. 
However, while the in vitro composition is maintained after 24 days, the tumor 
compositions are altered such that all tumors are composed, primarily, of clone 4T1-I. 4T1-
I’s accelerated proliferation was subsequently recapitulated when the lines were, 
individually, orthotopically injected and it showed the greatest corresponding differential of 
tumor volumes between 14 and 24 days (Fig. 4.6a). 
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Figure 4.4: Morphology and proliferation rates of all clonal lines 
10X microscopic phase-contrast images of the 23 clonal lines. Doubling times (DT), as 
calculated over a three-day period, are color coded in the image borders.  
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Figure 4.5. Focused analysis of a subset of 4T1 clones throughout metastatic disease 
progression 
(a) Strategy for isolating individual molecularly barcoded 4T1 clones. (b) A comparison of 
the relative proportions of the isolated clonal lines in vitro and in orthotopic primary tumors 
at 14 and 24 days. Columns represent biological replicates. (c) A comparison of clonal line 
proportions amongst the CTCs in the blood as well as the secondary lesions in lymph-node 
(LN), brain, liver and lung of animals corresponding to the tumors extracted at 24 days 
described in (b). (d) Subclonal analysis of 4T1-L, -E and -T cells via secondary barcode 
library infection. Each clonal line was separately infected with a second barcode library, 
pooled with the 22 other lines and then analyzed for sub-clonal populations via analysis of 
the secondary library. (e) Immunoflourescence analysis for mCherry in lung metastases 
resulting from each of the three pooled injections discussed in (d). mCherry is expressed in 
the secondary barcode library.  
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Figure 4.6: Tumor growth and metastases rates for individually injected clones 
(a) Primary tumor volumes resulting from orthotopically injected individual clonal cell lines. 
Measurements were taken 14 and 24 days after injection. (b) The percentage of lung 
metastatic burden for the animals discussed in (a) 24 days after injection. (c) A comparison 
of the clonal composition of lung metastases when the pool of 23 clonal lines was 
orthotopically injected (bottom panel) vs. injected into the left cardicac ventricle of mice (top 
panel).  
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Figure 4.5c depicts the composition of the blood and secondary lesions, and one can 
see that this small system recapitulates the results of the large-scale trial discussed in Figure 
4.1.  First, a clone’s abundance in the primary tumor does not correlate with its capacity to 
intravasate the cardiovascular system or form secondary lesions (e.g. 4T1-I is absent from all 
secondary sites). Second, the ability of individual clones within the population to 
intravasate the cardiovascular system is a driving force in determining the final population 
of blood-born metastases and in producing clonal tropism between the lymph-node and 
blood-born metastases. This is striking in this system where 4T1-E and -T dominate the CTC 
population, only 4T1-T is present at blood-born secondary lesions, but neither is present in 
the lymph-node. 4T1-T’s proclivity to form blood-born metastases was further confirmed 
when the lung metastatic burden of the mice discussed for Figure 4.6a was quantified (Fig. 
4.6b). In addition, the effect that an intravasation step has on the heterogeneity of secondary 
lesions was further confirmed when the pool of clones was injected into the left cardiac 
ventricle of mice. Under these conditions an entirely different clonal distribution is observed 
at the secondary lesion (Fig. 4.6c). 
To assess how the complexity of representative lines are affected at each selection 
stage, we infected each of the clonal lines 4T1-E, -L and -T with a second barcode library (Fig. 
4.1a), pooled them separately with the remaining 22 lines and, separately, orthotopically 
injected the resultant three pools. The number of engrafted 4T1-E, -L and -T sub-clones was 
found to be similar (Fig. 4.5d). However, selection for the ability to intravasate the 
cardiovascular system resulted in a significant reduction in the number of 4T1-L clones in 
the blood (p-value < 0.001). Finally, selection for the ability to extravasate into the lung 
resulted in 4T1-E being significantly reduced in clone-number (p-value < 0.001). Only 4T1-T 
subclones gave rise to abundant lung metastases. Though we observe some loss in 
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complexity at each stage of the metastatic process, the proclivities of each line are general 
properties of many, if not all, cells within the clone. This suggested that profiling these 
populations could provide clues to the mechanistic basis of their differential abilities. The 
results of the combined selection steps are depicted visually in Figure 4.6e, where lungs 
corresponding to the three pools were stained for mCherry, which is expressed in the 
second barcode library. 
The chromosomal integration site of some of the barcodes including 4T1-E, -L and –T 
were evaluated and are listed in Table 4.1. Most of the barcodes were inserted outside of 
genes. The 4T1-T barcode was inserted in the Outer dense fiber protein 2-like isoform 1/2. 
There are no indications in any publications that this gene is important for tumor or 
metastasis development.   
 
Transcriptional profiling of clonal cell lines 
A qualitative analysis of the clonal lines revealed that, while the majority of cells 
displayed clear epithelial or mesenchymal morphologies, 4T1-E and 4T1-T (along with 4T1-
U) displayed an “organoid” morphology (Fig. 4.4, p-value = 0.0119), hinting that clones 4T1-
E and -T share characteristics that promote intravasation. To ascertain these drivers, we 
performed RNA-seq on all lines and identified genes significantly overexpressed in 4T1-E 
and -T as compared to at least half of the remaining lines. In addition, RNA-seq was 
performed on matched primary tumors and lung metastases to identify genes significantly 
up-regulated at secondary lesions. These gene sets were then intersected to define a set of 12 
genes associated with intravasation into the cardiovascular system (Fig. 4.7a).  
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Table 4.1: Chromsomal integration sites of 4T1 clonal cell lines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Clone	  
(4T1-­‐)	  
	  
Chromosomal	  Integration	  site	  
	  
B	   Within	  Early	  endosome	  antigen	  1	  
E	   68586	  bp	  at	  5'	  side:	  interferon	  epsilon	  precursor	  188052	  bp	  at	  3'	  side:	  S-­‐methyl-­‐5'-­‐thioadenosine	  phosphorylase	  
I	   Within	  RNA-­‐binding	  protein	  40	  
K	   78837	  bp	  at	  5'	  side:	  Rho	  GTPase-­‐activating	  protein	  21	  isoform	  1132146	  bp	  at	  3'	  side:	  Enkurin	  
L	   16181	  bp	  at	  5'	  side:	  Cell	  division	  control	  protein	  42	  homolog	  isoform	  2	  43229	  bp	  at	  3'	  side:	  Uncharacterized	  protein	  LOC242711	  precurdor	  
O	   15527	  bp	  at	  5'	  side:	  Uncharacterized	  protein	  LOC101056086	  2813	  bp	  at	  3'	  side:	  Cadherin-­‐11-­‐like	  
R	   95328	  bp	  at	  5'	  side:	  Type-­‐2	  angiotensin	  II	  receptor	  123447	  bp	  at	  3'	  side:	  Amino	  acid	  transporter	  ATB0+	  
T	   Within	  Outer	  dense	  fiber	  protein	  2-­‐like	  isoform	  1/2	  
W	   Within	  Myb-­‐related	  protein	  B	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Figure 4.7. Serpine2 and Slpi are regulators of intravasation into the cardiovascular 
system. (a) Gene expression analysis (via RNA-seq) of each clonal line as well as matched 
tumor and lung metastases to identify genes upregulated in 4T1-E and -T as compared to 
the other clones and in lung metastases as compared to primary tumors.  All data points 
above the red dotted line represent at least a 2-fold increase. (b) Analysis of Serpine2 and 
Slpi human orthologs SERPINE2 and SLPI, respectively in patients with no relapse as 
compared to patients with relapse in the lung. (c) Relative proportions of clonal lines in the 
CTCs and lung where 4T1-T has as been infected with non-targeting shRNAs and shRNAs 
targeting Serpine2 and Slpi. (d) Representative H&E stained lung sections from BALB/c 
mice that had been orthotopically injected with 4T1 cells that had been infected with a non-
targeting shRNA and a vector harboring shRNAs for both Serpine2 and Slpi.  
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Expression levels of our 12 candidates were additionally examined in human 
patients, comparing those that did or did not relapse with lung metastases (Harrell et al. 
2012). Of the 10 genes with associated patient data, the human orthologs of Serpine2 and 
Slpi (SERPINE2 and SLPI, respectively) emerged as the most significantly overexpressed in 
relapsed patients (Fig. 4.7b, p-value < 0.005). The 4T1 cell line is used to model aggressive 
breast cancer subtypes such as Basal, Her2, and Claudin-Low. Notably, it is precisely these 
tumor types, and not luminal cancers, that show increased SERPINE2 and SLPI expression 
in patients that relapse. 
 
Functional validation of Serpine2 and Slpi on lung metastasis 
To functionally validate Slpi and Serpine2 as regulators of intravasation, 4T1-T cells 
were separately infected with two shRNAs for each gene as well as a control shRNA 
targeting Renilla luciferase (Fig. 4.1c). The separately infected cells were then pooled in 
equal amounts, orthotopically injected and after 18 days the primary tumors, blood and 
lungs were removed and their corresponding shRNA abundances quantified via NGS. A 
comparison of shRNA levels in the tumor vs. the blood and lungs shows a significant 
depletion of all targeting shRNAs after intravasation (Fig. 4.8a, p-value < 0.01).  When the 
same pool of cells was injected into the left cardiac ventricle, no depletion of targeting 
shRNAs was observed in the resultant lung metastases as compared to the injection pool, 
further validating Serpine2 and Slpi as being regulators of intravasation alone (Fig. 4.8b). 
 To further examine how Serpine2 and Slpi expression shapes this system, the five 
individually shRNA infected 4T1-T populations were pooled separately with the 22 
remaining clonal lines. Each of these five pools, were then orthotopically injected and the 
clonal analysis as described in Figure 4.5b,c was performed.  Figure 4.7c demonstrates that  
	   90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: Serpine2 and Slpi shRNAs abundances in lung and CTCs after orthotopic and 
intracardiac injection 
(a) Proportions of shRNA targeting Renilla luciferase, Serpine2 and Slpi that had been 
infected separately into 4T1-T cells. After selection the separately infected cells were pooled 
in equal amounts with the remaining 22 clonal lines and orthotopically injected into mice. 
The proportions are in comparison to the primary tumor. (b) Relative proportions of the 
shRNA infected cells in lung metastases (as compared to the pre-injection pool) 8 days after 
being injected into the left cardiac ventricle.  
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depletion of Serpine2 and Slpi in 4T1-T cells resulted in a significant decrease in their 
representation within the CTCs and lung metastases (p-value < 0.01). In addition, there was 
a significant reduction in mCherry positive lung nodules (representing shRNA infected 4T1-
T cells) in samples corresponding to targeting shRNAs (Fig 4.9a,b, p-value < 0.05).   
Finally, to assess how Serpine2 and Slpi act globally across all clones in the 4T1 
system in an immune competent setting, 4T1 parental cells were infected with each of the 
five shRNAs described above as well as with tandem-shRNA vectors harboring 
combinations of Serpine2 and Slpi targeting shRNAs (Fig 4.1d). These cells were 
orthotopically injected, and after 18 days secondary lesions in the lung were quantified on 
H&E stained slides. Lungs corresponding to single gene knockdowns showed significant 
(~50 %, p-value < 0.01) reduction in metastases, and those corresponding to double-
knockdowns showed and even more significant (~60%, p-value < 0.005) reduction in 
secondary lesions (Fig. 4.7d and 4.9c,d). 
Notably, a recent study also implicated Serpins, including Serpine2, in metastasis of 
breast cancer to the brain (Valiente et al. 2014).  These investigators were unable to block 
metastasis by knockdown of Serpine2.  However, in those studies, cells were introduced by 
intracardiac injection, a procedure that bypasses the requirement for increased Serpine2 
expression. 
 
Tumor vasculature and leakiness of clonal cell lines 
CD31 is an endothelial cell marker and a major component of their intercellular 
junctions (Simmons et al. 1990). A qualitative analysis of CD31 stained clonally derived 
tumor sections revealed a higher number of vessels with focal loss of CD31 staining in 4T1-E 
and -T tumors, indicating that the vasculature in these tumors might be altered. We wished  
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Figure 4.9: Lung metastatic burden of 4T1-T cells or parental 4T1 cells targeted with 
Serpine2 and/or Slpi shRNAs 
(a) Representative mCherry stained sections of the lungs from animals that had been 
injected with a pool of the 23 clonal lines. In each case, the 4T1-T cells in the pool had been 
infected with an shRNA targeting Renilla luciferase, Serpine2 or Slpi. The shRNAs were 
harbored in a vector that constitutively expressed mCherry. (b) Quantification of all 
mCherry positive metastatic lung nodules in all mice. (c) Representative H&E stained lung 
sections from animals that had been orthotopically injected with parental 4T1 cells. In each 
case the cells were infected with a retroviral vector constitutively expressing an shRNA 
targeting Renilla luciferase, Serpine2 or Slpi or a tandem vector targeting both Serpine2 and 
Slpi. (d) Quantification of the number of metastatic nodules in all H&E stained sections 
described above.  
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to quantify these observations and we reasoned that in tumors where vasculature is altered, 
a higher degree of vascular leakiness should be observed. Thus, we developed and qualified 
an analysis pipeline to assign a leakiness index to tumors using a high molecular weight 
dextran (see Methods). Using this pipeline we determined that the leakiness of 4T1-T 
derived tumors was significantly higher than in 4T1-L derived tumors (Fig 4.10a,b and 
4.11a). Silencing of Serpine2 or Slpi resulted in a reduction in leakiness, implicating these 
proteins as drivers of this vascular phenotype (Fig. 4.11b, p-value < 0.05). 
We hypothesized that direct contact of tumor cells with blood, due to tumor 
leakiness, might result in tumor cells being passively drawn into the bloodstream to form 
CTCs. To test this hypothesis the clonal lines were pooled and orthotopically injected into 
three mice cohorts. One cohort received regular drinking water while the other two received 
drinking water with 10 mg/L warfarin (mimicking tumor leakiness because of the inability 
to coagulate blood properly). At this dose all animals survive, prothrombin activator 
fragments F1 + F2 are reduced by > 80% in the plasma, and a significant increase in tumor 
leakiness is observed (Fig. 4.12a,b,c). One treated cohort began treatment 1 day prior to 
injection and the other 10 days post-injection. In addition, cells were injected through the 
left cardiac ventricle of three additional cohorts, and these received the same warfarin dose-
regimes listed above. 
Previous work has shown that, due to a reduction in clotting in the lung, when cells 
are injected directly into the blood, a decrease in metastases is observed when warfarin is 
administered (McCulloch and George 1987; Bobek and Kovarík 2004; Mousa 2006). This 
result was recapitulated in mice that were injected via the left cardiac ventricle (Fig. 4.12d, 
p-value < 0.001).  In contrast, when intravasation was made a requirement (via orthotopic 
injection), administration of warfarin significantly increased the lung-metastatic burden (Fig. 
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Figure 4.10: Vascular leakiness in 4T1-L and 4T1-T primary tumors 
(a) DAPI and Dextran, Alexa 647 (+ MERGED) stained tumor sections from orthotopic 
tumors derived from 4T1-L and –T cells. (b) Leakiness Index of primary tumors resulting 
from orthotopic injection of 4T1-L or –T cells.  
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Figure 4.11. Vascular mimicry drives metastatic progression 
(a) Vascular leakage in sections taken from primary tumors derived from clonal lines 4T1-L 
and –T that were intravenously injected with high molecular weight Dextran, Alexa 647. (b) 
The leakiness index (see Methods) of primary tumors derived from 4T1-T cells that have 
been infected with either a non-targeting shRNA or an shRNA targeting Serpine2 or Slpi. (c) 
CD31 + PAS stained section of a 4T1-T derived primary tumor. Green arrow indicates a 
CD31 positive blood vessel. Blue arrow indicates a CD31 negative, PAS positive channel. (d) 
Quantification of CD31-/PAS+ channels in clonally derived tumors from each clonal line. 
(e) Images of Parental 4T1, 4T1-L, 4T1-E and 4T1-T cells grown on matrigel.  
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Figure 4.12: Effect of Warfarin on metastatic progression  
(a) Reduced levels of cleaved Prothrombin F1 + F2 (active component of blood coagulation) 
upon administration of Warfarin in drinking water. (b) Vascular leakage in sections taken 
from primary tumors derived from all 23 clonal lines that were intravenously injected with 
high molecular weight Dextran, Alexa Fluor 647. Animals were administered drinking 
water either with or without Warfarin. (c) Leakiness Index of primary tumors resulting from 
orthotopic injections of all 23 clonal lines. (d) Counts of lung metastatic nodules from 
animals there were injected intravenously with all 23 clonal lines and were treated either 
with or without Warfarin. (e) Counts of lung metastatic nodules from animals there were 
injected orthotopically with all 23 clonal lines and were treated either with Warfarin pre- or 
post-injection or without Warfarin. (f) CTC abundance (measured by qPCR) from animals 
that were injected orthotopically with all 23 clonal lines and were treated either with 
Warfarin pre- or post-injection or without Warfarin. 
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4.12e). Further, via qPCR of whole blood for sequences within the barcode-harboring vector, 
we determined that this was the result of an increased CTC load (Fig. 4.12f). Finally, an 
analysis of barcodes showed that 4T1-E and -T remained pervasive in the blood of the 
warfarin treated animals, indicating that they were preferentially drawn into the blood 
stream by the treatment (Fig 4.13). This was taken as evidence that these clones are likely in 
close proximity to sites of vascular leakiness in the primary tumor. 
 
Vascular mimicry of clonal cell lines 
The characteristics of 4T1-E and -T derived tumors, namely focal loss of CD31 in 
vessels and a high degree of tumor leakiness, have been associated with a recently described 
phenomenon termed vascular mimicry (VM), where tumor cells differentiate into 
endothelial-like cells and form extracellular matrix (ECM) rich tubular structures to carry 
blood from the vasculature to hypoxic regions of the tumor (Fig. 4.11c) (Maniotis et al. 1999; 
Folberg et al. 2000; Hendrix et al. 2003; Francescone et al. 2011). We hypothesized that the 
ability of 4T1-E and –T cells to intravasate was the result of a heightened capacity for VM. 
This would place the cells in direct contact with the blood, which we have demonstrated 
above results in increased intravasation. To test this hypothesis we assessed CD31 + 
Periodic acid–Schiff (PAS) stained sections of clonally derived tumors from all lines for 
characteristics consistent with VM (see Methods).  This analysis revealed a striking increase 
in these characteristics for 4T1-E and –T tumors as compared to the others (Fig. 4.11.d and 
4.14a-e, p-value < 0.001).  
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Figure 4.13: Clonal barcode composition upon Warfarin treatment  
Barcode representation of animals that were orthtopically injection with a mix of all 23 
clonal lines and were treated either with Warfarin pre- or post-injection or without Warfarin. 
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Figure 4.14: Vascular mimicry in 4T1-E and 4T1-T primary tumors 
(a) Periodic acid-Schiff (PAS) staining of 4T1-E derived primary tumors. Arrows indicate 
networks of open channels bordered by thin PAS positive extracellular matrix. (b) PAS 
staining of a 4T1-T derived primary tumor. Arrows indicate the same PAS positive channels 
as described in (a). (c) Black and white image of PAS stained 4T1-E derived primary tumors. 
Arrows indicate anastomosing vascular channels. (d) Black and white image of PAS stained 
4T1-T derived primary tumors. Arrows indicate anastomosing vascular channels. e. CD31 + 
PAS stained 4T1-T derived primary tumor. Light blue arrows indicate vessels with 
interrupted CD31 staining. Dark blue arrows indicate CD31 negative PAS positive   
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When human umbilical vein endothelial cells (HUVEC) are grown on matrigel they 
form a rich tubular network, just as do tumor cells capable of vascular mimicry (Fig. 4.15a) 
(Maniotis et al. 1999; Francescone et al. 2011). We decided to apply this method to assess 
4T1-E and T’s capacity for VM. When parental 4T1 cells were plated there was weak 
evidence for VM and when the non-intravasating clone 4T1-L was plated in matrigel no 
evidence for VM was observed (Fig. 4.11e). In contrast, when 4T1-E or 4T1-T cells were 
plated, strong evidence for VM was observed, validating the analysis performed in Figure 
4.11d. 
To determine if Serpine2 or Slpi promote VM, we plated the 5 shRNA infected 4T1-T 
cell lines on matrigel. The cells infected with the non-targeting shRNA formed strong 
tubular networks. In contrast almost all evidence for VM was abolished in cells infected 
with the targeting shRNAs (Fig. 4.16a). Taken together with the data presented in Figure 
4.5c,d this indicates that clone 4T1-E and T’s proclivity for intravasation is the result of 
Serpine2 and Slpi driven VM.  
Next, to determine if an increased expression of Serpine2 and/or Slpi might promote 
VM and intravasation in non-intravasating clones we overexpressed Serpine2 and Slpi in 
4T1-B, F, N and S cells. We determined that in all cases, when Serpine2 or Slpi were over 
expressed, a significant increase in VM resulted (Fig. 4.16b, p-value < 0.05). In addition, to 
test if this same phenomenon could be observed in human cells, we also overexpressed the 
two splicing variants of SERPINE2 as well as SLPI in three human breast cancer lines: MDA-
MB-231 (Basal), MDA-MBA-436 (Basal) and T47D (Luminal). We hypothesized that since 
expression of SERPINE2 and SLPI is only predictive of relapse in aggressive tumors (Fig. 
4.7b) that only the Basal cell lines would respond to over expression. True to our hypothesis, 
in both Basal cell lines a significant increase in VM was observed when over expression was 
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Figure 4.15: Tube formation assay of human breast cancer cells upon overexpression of 
SERPINE2 and SLPI 
(a) Human umbilical vein endothelial cells (HUVEC) plated on matrigel to assess tube 
formation ability. (b) MDA-MB-231 cells infected with an empty overexpression vector 
plated on matrigel (upper panel) and MDA-MB-231 cells overexpressing SERPINE2 
(transcript NM_0016216) plated on matrigel (lower panel). (c) Full quantification of tubular 
structures in basal cell lines MDA-MB-231 and MDA-MB-436 when infected with an empty 
overexpression vector or when infected with vectors for overexpressing SERPINE2 
(transcript NM_0016216), SERPINE2 (transcript NM_001136528) or SLPI. 
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Figure 4.16. Serpine2 and Slpi2 drive vascular mimicry 
(a) Number of tubular structures identified per 5X microscopic field when 4T1-T cells had 
been infected with a non-targeting shRNA or shRNAs targeting Serpine2 or Slpi and grown 
on matrigel.  (b) Number of tubular structures identified per 5X microscopic image when 
non-intravasating 4T1 clonal lines have been infected with an empty retroviral vector or 
vectors for overexpression of Serpine2 or Slpi. (c) Relative CTC proportions of the cells 
described in G after they had been pooled with the remaining clonal lines and orthotopically 
injected. 
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induced, however no evidence for VM was observed in the Luminal line (Fig. 4.15b,c, p-
value < 0.05).  
Finally, we wished to determine if the induced increase in VM in 4T1-B, F, N and S 
cells resulted in their having an increased proclivity to intravasate. The clones over-
expressing Slpi, Serpine2 as well as those harboring an empty vector were separately pooled 
with the remaining 19 clonal lines (with the exception of 4T1-E, to more easily detect 
increases in the overexpressing clones intravasation). The pools were then orthotopically 
injected and, after 18 days, the clone profiles of the tumors and blood were profiled. True to 
the hypothesis that VM drives intravastaion, with the exception of 4T1-F, an increase in VM 
resulting from overexpression of Serpine2 or Slpi resulted in an increased capacity for 
intravasation (Fig. 4.16c, p-value < 0.05). 
 
General conclusions 
We have described a mouse model of breast tumor heterogeneity, which allows us to 
probe the molecular basis of stable differences in the ability of clonal populations to 
contribute to various aspects of disease.  In this initial study, we focused on those 
characteristics distinguishing clones that efficiently contribute to CTCs, a subset of which 
also form metastases.  The ability to form CTCs, and ultimately metastases, is closely linked 
to the capacity for vascular mimicry.  Tumor cell lined vasculature has shown a strong 
clinical correlation with advanced stage disease and poor clinical outcome (Cao et al. 2013).  
In our model, vascular mimicry is driven by increased expression of two secreted proteins, 
Serpine2 and Slpi. Very little is currently known of the molecular determinants that enable 
vascular mimicry, and Serpine2 and Slpi are among the first validated drivers of this process. 
These proteins are both serine protease inhibitors, and the precise mechanism by which they 
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might confer vascular mimicry is unclear, though Serpine2 promotes ECM production and 
VM channels are ECM-rich (Hendrix et al. 2003; Buchholz et al. 2003). Both Serpine2 are Slpi 
are also anticoagulants (Bouton et al. 2012; Masuda et al. 1995).  Thus, they may also play a 
role in keeping open an interface between a tubule created by tumor cells and the tumor 
vasculature, allowing passage of both red blood cells into the tumor and cancer cells into the 
bloodstream.  Notably, these dual roles of vascular mimicry link promotion of metastasis to 
satisfaction of a need of the primary tumor, essentially providing a way in which metastatic 
potential might be positively selected during the process of primary tumor formation. 
Others are making great strides in growing patient material in various culture 
systems. It is our hope that by applying these technologies we will be able to apply this 
method to patient material to identify the most likely cells to metastasize so that treatment 
strategies can be adjusted accordingly.  
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Methods 
Cell culture 
The mouse mammary tumor cell line 4T1 (ATCC) and any derived clonal cell line 
were cultured in DMEM high glucose (Life Technologies) supplemented with 5% fetal 
bovine serum (Thermo Scientific), 5% fetal calf serum (Thermo Scientific), non-essential 
amino acids (Life Technologies) and penicillin streptomycin (Life Technologies). Human 
breast tumor cell lines MDA-MB-231, MDA-MB-436 and T47D (ATCC) were cultured in 
DMEM high glucose supplemented with 10% fetal bovine serum, non-essential amino acids 
and penicillin streptomycin. Human umbilical vein endothelial cells (HUVEC) (Lonza) were 
cultured in EBM-2 media with the EGM-2 Bulletkit (Lonza). HUVEC cells were used within 
3 passages. Platinum-A (Cell BioLabs) and 239-FT (Life Technologies) packaging cell lines 
were cultured in DMEM high glucose supplemented with 10% fetal bovine serum and 
penicillin streptomycin. 
 
Virus production 
All retroviral vectors were packaged using Platinum-A packaging cells. The 
lentiviral barcode library was packaged using 293-FT lentivirus packaging cells. Cells were 
plated on 15 cm adherent tissue culture plates (Corning) ~5 hours before transfection at a 
confluency of ~70%. A transfection mixture was prepared with viral vector (75 µg), VSV-G 
(7.5 µg), 2M calcium chloride (187.5 µl) (Sigma-Aldrich) and, when transfecting shRNA 
harboring vectors, 20 nM siRNAs targeting Pasha (200 µl) (Qiagen). The mixture was 
brought to 1.5 ml with H20 and then added drop-wise to the same amount of 2x HBS while 
being bubbled. One liter of 2X HBS was prepared with 280 mM NaCl, 50 mM HEPES, 1.5 
mM Na2HPO4, 12 mM Dextrose and 10 mM KCl (Sigma-Aldrich), then adjusted to a pH of 
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7.02. After the transfection mixture was added to the HBS, vigorous bubbling continued for 
30 - 60 seconds. After letting the resultant mixture stand for 15 minutes, it was added to the 
packaging cells along with 100 mM chloroquin (7.5 ul) (Sigma-Aldrich). After 14 hours, 
media was replaced. 30 hours after media change, virus was collected and filtered through a 
0.45 µm filter (EMD Millipore) and stored at 4°C. 
 
Establishment of clonal cell lines 
30 million 4T1 cells were infected with the lentiviral barcode library (Fig. 4.2a) at a 
multiplicity of infection (MOI) of 0.3. Single cells were sorted using the FACSAria IIU cell 
sorter (BD Biosciences) into 96 well plates. Clonal cell lines were minimally expanded and 
frozen down. For all experiments, each clonal cell line was used within 7 passages. The 
barcode of each individual clonal cell line was determined by Sanger sequencing. Forward 
primer Comp-Mir5: 5- CAG AAT CGT TGC CTG CAC ATC TTG GAA AC -3 and reverse 
primer Comp-WPRE: 5- ATC CAG AGGTTG ATT GTT CCA GAC GCG T -3.  
 
Clonal cell line proliferation rates 
Proliferation assays were performed by counting viable cells over 72 hours. 1 x 105 
cells were plated in duplicates and were counted using the MACSQuant Analyzer (Miltenyi 
Biotec). 
 
Chromosomal integration site 
Genomic DNA from each clone was isolated using the QIAamp DNA blood mini kit 
(Qiagen). Choromosmal integration sites were determined using the Retrovirus Integration 
Site Analysis Kit (Clontech).  
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Animal studies 
All mouse experiments were approved by the Cold Spring Harbor Animal Care and 
Use Committee. All orthotopic injections were performed using 1 x 105 mouse mammary 
tumor cells resuspended in 20 ul of a 1:1 mix of PBS and growth factor reduced Matrigel 
(BD Biosciences). Injections were into mammary gland #4 of 8 week-old female NOD scid 
gamma mice (JAX). For intracardiac injections, 1 x 105 mouse mammary tumor cells were 
resuspended in 200 ul of PBS and injected into the left cardiac ventricle. For tail vein 
injections, 5 x 105 mouse mammary tumor cells were resuspended in 100 ul of PBS. 
 
For clonal pooling experiments, clonal cell lines were counted in duplicate using the 
MACSQuant Analyzer (Miltenyi Biotec). Equal numbers of cells were pooled together for 
injection. A pre-injection pool was collected to validate equal representation of each clone 
before injection. Tumor, lung, brain, liver, brachial lymph node and blood were harvested 
from mice for further processing. Primary tumor volume was measured using the formula V 
= 1/2(LxW2), where L is length and W is width of the primary tumor. Warfarin (10 mg/L, 
Sigma-Aldrich) was administered with drinking water and changed every 3 days.  
 
Quantification of lung metastatic burden 
The lung metastatic burden of individual clones injected into the mammary gland 
was evaluated in five-micron sections stained with a standard H&E protocol. Four mice 
were evaluated per clone. Quantification was performed using ImageJ Software (NIH) 
converting images to 8-bit. Upper and lower thresholds for each image were adjusted to 
determine total lung area and adjusted again to determine the metastatic area. Both values 
were used to obtain relative metastatic areas.  
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For other experiments, the lung metastatic burden was evaluated by counting the 
number of metastatic nodules in the lung. For this, five-micron sections were stained with a 
standard H&E protocol. For all experiments, ten mice were evaluated per condition. 
 
Barcode and shRNA analysis 
Genomic DNA was isolated using phenol chloroform extraction for all tissues except 
blood. Genomic DNA for blood was isolated using the QIAamp DNA Blood Mini Kit 
(Qiagen).  
 
The barcodes of the retroviral library (Fig. 4.2a) were amplified using a one-step PCR 
protocol. For each sample, 96 individual PCR reactions of 200 ng of genomic DNA were 
carried out using KOD Polymerase (EMD Millipore). Forward primer: 5- AAT GAT ACG 
GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC T -3 
and reverse primer: 5- CAA GCA GAA GAC GGC ATA CGA GAT NNN NNN GTG ACT 
GGA GTT CAG ACG TGT GCT CTT CCG ATC -3. The reverse primer contained a barcode 
(NNNNNN) that enabled multiplexing with standard Illumina Truseq chemistry and 
software. The PCR was carried out for 30 cycles and PCR products were purified using a 
PCR purification kit (Qiagen). PCR products were size selected on an E-gel SizeSelect 2% 
agarose gel (Life Technologies), and sequenced on the Illumina HiSeq sequencer generating 
22 nt single-end (SE) reads. 
 
The barcodes of the lentiviral library (Fig. 4.2b) were amplified using a two-step PCR 
protocol. For each sample, eight individual PCR reactions of 200 ng of genomic DNA were 
carried out using KOD Polymerase (EMD Millipore). Forward primer 1: 5- GTG ACT GGA 
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GTT CAG ACG TGT GCT CTT CCG ATC TCA GAA TCG TTG CCT GCA CAT CTT GGA 
AAC -3 and reverse primer 1: 5- ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT 
ATC CAG AGG TTG ATT GTT CCA GAC GCG T -3. The first PCR was carried out for 25 
cycles. PCR products were purified using the PCR purification kit (Qiagen). The second 
PCR was performed using 500 ng of PCR product from the first PCR. Forward primer 2: 5- 
AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT 
CCG ATC T -3 and reverse primer 2: 5- CAA GCA GAA GAC GGC ATA CGA GAT NNN 
NNN GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATC -3. The reverse primer 
contained a barcode (NNNNNN) that enabled multiplexing with standard Illumina Truseq 
chemistry and software. The second PCR was carried out for 25 cycles and PCR products 
were again purified using the PCR purification kit (Qiagen). PCR products were size 
selected on an E-gel SizeSelect 2% agarose gel (Life Technologies), and sequenced on the 
Illumina HiSeq sequencer generating 22 nt single-end (SE) reads. 
 
For Figure 4.1 and 4.5d, the vector library was sequenced at high depth. For each 
experiment the corresponding fastq file was aligned to the vector library with the Bowtie 
software, allowing 3 mismatches. Each experimental read was then assigned to the most 
abundant vector sequence that it mapped to. For Figure 4.1 only sequences that were 
present with a count greater than or equal to 5 in all tumors were analyzed.  
 
For Figure 4.3b,c abundant clones were identified by fitting a mixed Gaussian model 
to the summed distributions described in Figure 4.3a. Abundant clones were those that then 
subsequently clustered into the Gaussian with the larger mean. 
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The shRNAs were amplified using the same two-step PCR protocol as described 
above for the lentiviral barcode library. Forward primer 1: 5- CAG AAT CGT TGC CTG 
CAC ATC TTG GAA AC -3 and reverse primer 1: 5- CTG CTA AAG CGC ATG CTC CAG 
ACT GC -3. Forward primer 2: 5- AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT 
AGC CTG CGC ACG TAG TGA AGC CAC AGA TGT A -3 and reverse primer 2: 5- CAA 
GCA GAA GAC GGC ATA CGA GAT NNN NNN GTG ACT GGA GTT CAG ACG TGT 
GCT CTT CCG ATC TCT GCT AAA GCG CAT GCT CCA GAC TGC -3. The reverse primer 
contained a barcode (NNNNNN) that enabled multiplexing. 
 
RNA-Seq library preparation and analysis 
Total RNA was purified and DNAse treated using the Qiagen RNeasy Mini Kit. 
RNA integrity (RNA Integrity score > 9) and quantity was measured on an Agilent 
Bioanalyzer (RNA Nano kit). The NuGEN Ovation RNA-Seq V2 protocol was carried out on 
100 ng of total RNA. cDNA was fragmented using the Covaris LE220 sonicator according to 
the manufacturer’s instruction to yield a target fragment size of 200 bp. The fragmented 
cDNA was subsequently processed using the NuGEN Ovation Ultralow DR Multiplex 
System. Each sample was sequenced on the Illumina HiSeq sequencer generating 76 nt 
single-end (SE) reads. 
 
Reads were aligned to the mm10 genome using the Bowtie-2 alignment tool. 
Mapped reads were then assigned to genes using HTSeq-count (using the latest version of 
RefSeq.gtf file for gene coordinates). Resultant counts were then normalized and compared 
using DESeq. For a gene to be considered over-expressed it had to show an at least 2-fold 
change with FDR < 0.05.   
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Isolation of matched tumor and lung tissue 
Tumor and lung tissue were harvested, minced and treated in DMEM high glucose 
containing 1x collagenase/hyaluronidase buffer (StemCell) and 10 U DNAse I (Sigma) for 1 
hour at 37 C. Cells were washed in HBSS (Life Technologies) two times and then re-
suspended in 4T1 cell culture media containing 60mM 6-Thioguanine. Cells were passaged 
for 5 days until all stromal cells died.  
 
shRNA knock-down and cDNA overexpression 
Mouse and human cell lines were transduced with amphotropically packaged 
retroviruses. MDA-MBA-231 and T47D cells were selected with 1500 mg/ml G418 and 
MDA-MD-436 cells were selected with 1000 mg/ml G418 for 1 week. All mouse clonal cells 
lines were selected with 1000 mg/ml G418 for 1 week, the parental 4T1 cell line was selected 
with 600 mg/ml G418 for 1 week. 
 
qRT-PCR 
Total RNA was purified and DNAse treated using the RNeasy Mini Kit (Qiagen). 
Synthesis of cDNA was performed using SuperScript III Reverse Transcriptase (Sigma). 
Quantitative PCR analysis was performed on the Eppendorf Mastercycler ep realplex. All 
signals were quantified using the ΔCt method and were normalized to the levels of Gapdh. 
 
qRT-PCR primers 
mouse Slpi (Exon 1-2): 
5'-GAC TGT GGA AGG AGG CAA A-3' 
5'-GGC ATT GTG GCT TCT CAA G-3' 
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mouse Slpi (Exon 3-4): 
5'-CAG TGT GAC GGC AAA TAC AAG-3' 
5'-GCC AAT GTC AGG GAT CAG G-3' 
 
mouse Serpine2 (Exon 3-4): 
5'-TCT GCC TCT GAG TCC ATC A-3' 
5'-AAC CGA GAC TTC CAC AAA CC-3' 
 
mouse Serpine2 (Exon 5-6): 
5'-TCA TCC CTC ACA TCA CTA CCA-3' 
5'-CTT TCA GTG GCT CCT TCA GAT-3' 
 
mouse Gapdh (Exon 2-3): 
5'-AAT GGT GAA GGT CGG TGT G-3' 
5'-GTG GAG TCA TAC TGG AAC ATG TAG-3' 
 
human SLPI (Exon 1-2): 
5'-TGT GGA AGG CTC TGG AAA G-3' 
5'-TGG CAC TCA GGT TTC TTG TAT C-3' 
 
human SERPINE2 (Exon 5-6): 
5'-GCC ATG GTG ATG AGA TAC GG-3' 
5'-GCA CTT CAA TTT CAG AGG CAT-3' 
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human GAPDH (Exon 2-3): 
5'-ACA TCG CTC AGA CAC CAT G-3' 
5'-TGT AGT TGA GGT CAA TGA AGG G-3' 
 
Figure 4.17 shows knock-down efficiencies of Serpine2 and Slpi shRNAs (mouse) and fold 
overexpression of Serpine2 and Slpi (mouse and human)  
 
Prothrombin Fragment 1+2 (F1+2) ELISA 
Blood was collected from animals that were treated with warfarin by cardiac heart 
puncture using 3.8% sodium citrate as an anticoagulant. Samples were centrifuged at 1000g 
for 15 min at 4 C. Blood plasma was isolated and stored at -80 C for further processing. 
Plasma samples were analyzed for Prothrombin Fragment 1+2 using the Mouse 
Prothrombin Fragment 1+2 (F1+2) ELISA kit (Kamiya Biomedical Company) according to 
manufacturer’s instructions. Each sample was measured in duplicates and each condition 
had four to five animals. 
 
mCherry analysis  
For immunoflourescence, five-micron sections of paraffin-embedded lungs were 
deparaffinized in xylene, rehydrated in an alcohol series and immersed in distilled water. 
The sections were then treated with high-temperature antigen retrieval in citrate buffer 
(pH 6), blocked with MaxBlock (ActiveMotif) for 1 hour at 37 C and incubated with primary 
antibody RFP Antibody Pre-adsorbed (1:100) (600-401-379, Rockland) overnight at 4 C.  
After washing, the slides were incubated for 1 h with Alexa 647 donkey anti-rabbit IgG 
(1:500) (A-31573, Life Technologies) and counterstained with DAPI (1 mg/ml) (Sigma- 
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Figure 4.17: Knock-down efficiency of Serpine2 and Slpi shRNAs and fold 
overexpression of SERPINE2 and SLPI cDNA 
(a) Knockdown efficiency of Serpine2 (as measured by qPCR) in parental 4T1 and 4T1-T 
cells after infection with each of the constructs harboring an shRNA targeting Serpine2. (b) 
Knockdown efficiency of Slpi (as measured by qPCR) in parental 4T1 and 4T1-T cells after 
infection with each of the constructs harboring an shRNA targeting Slpi. (c) Fold over-
expression of Serpine2 and Slpi in parental 4T1 as wells as 4T1-B, F, N and S cells after 
infection with overexpression vectors harboring Serpine2 and Slpi cDNA (as calculated 
relative to cells infected with empty vectors). (d) Fold overexpression of SERPINE2 
transcripts 1 (transcript NM_006216) and 2 (transcript NM_001136528) as well as SLPI in 
MBA-MD-231, MBA-MB-436 and T47D cells after infection with overexpression vectors 
harboring SERPINE2 transcripts 1 and 2 as well as SLPI cDNA (as calculated relative to cells 
infected with empty vectors). The high relative expression of SLPI in MDA-MB-231 cells 
infected with the SLPI overexpression vector is due to near zero SLPI levels in the parental 
cell line.  
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Aldrich) for 5 minutes. Slides were mounted with ProLong Gold antifade reagent (Life 
Technologies) and cover-slipped. Sections were scanned on the AperioFL Fluorescence Slide 
Scanner (Aperio). 
For immunohistochemistry, the same initial steps were followed as for 
immunofluorescence. The slides were then blocked with 2.5% ready-to-use normal horse 
serum from ImmPRESS Anti-Rabbit Ig (peroxidase) Polymer Detection Kit (MP-7401, Vector 
Laboratories) for 1 hour and then incubated with primary antibody RFP Antibody Pre-
adsorbed (1:200) (600-401-379, Rockland) overnight at 4 C.  After washing, the slides were 
incubated with secondary antibody from the previous kit for 30 minutes, rinsed, and 
developed with chromogen ImmPACT DAB Peroxidase Substrate for staining (SK-
4105, Vector Laboratories) until the desired intensity was achieved. Slides were 
counterstained with hematoxylin and coverslipped. Sections were then scanned on the 
Aperio Light Field Slide Scanner (Aperio) for further quantification.  
 
Omission of the primary antibody was used as a negative control in both cases. 
 
CD31 and Periodic acid-Schiff analysis 
Five-micron sections of paraffin-embedded lungs were de-paraffinized in xylene, 
rehydrated in an alcohol series and immersed in distilled water. The sections were then 
treated with high-temperature antigen retrieval in citrate buffer (pH 6), blocked with 2.5% 
ready-to-use normal horse serum from ImmPRESS Anti-Rabbit Ig (peroxidase) Polymer 
Detection Kit (MP-7401, Vector Laboratories) for 1 hour and incubated with primary 
antibody against CD31 (1:400) (28364, Abcam) overnight at 4 C.  After washing, the slides 
were incubated with secondary antibody from the previous kit for 30 minutes, rinsed, and 
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developed with chromogen ImmPACT DAB Peroxidase Substrate for staining (SK-
4105, Vector Laboratories) until the desired intensity was achieved. Slides were then stained 
with Periodic Acid-Schiff (PAS) Kit (Sigma) according to manufacturer’s instructions. 
Sections were then scanned on the Aperio Light Field Slide Scanner (Aperio) for further 
analysis. Omission of the primary antibody was used as a negative control. 
 
Two tumors from each clone and the parental cell line were evaluated for evidence 
of vascular mimicry.  PAS staining, H&E staining, and CD31 immunohistochemistry were 
used to evaluate the presence and extent of mimicry as previously described (Folberg et al. 
2000; Hendrix et al. 2003; Maniotis et al. 1999). Five random 40X fields from 2 different 
tumors (ten total fields) of each clone were scored for the number and size of areas with 
morphology consistent with mimicry.  The criteria used was 1) PAS positive channels that 
contain red cells and fluid, 2) the absence of CD31 staining in these channels, and 3) the 
polarization of tumor cells on an indistinct or imperceptible matrix lining vascular channels 
with red cells and/or fluid and no evidence of endothelization or tumor cells lining vascular 
spaces with no evidence of a matrix. 
 
Vascular leakage  
To visualize vascular leakage in the primary tumor, 100 µl of Dextran Alexa 647, 10 
kDa (1 mg/ml in PBS) (Life Technologies) were injected into mice by tail vein injection. 
Three minutes later, mice were perfused with 4% PFA. After fixation, tumors were 
harvested and put in 4% PFA overnight at 4 C. After this, samples were infiltrated with 20% 
sucrose overnight at 4 C. Tumors were frozen in OCT compound (Sakura Finetek) and 25 
um thick sections were cut, washed, incubated with DAPI (1 mg/ml) (Sigma-Aldrich) and 
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mounted in ProLong Gold antifade reagent (Life Technologies). Sections were examined 
under the LSM 780 Confocal microscope (Zeiss). 
 
An average of five to seven fields were taken from each sample. Each condition 
consisted of four to five animals (20 to 35 total fields). Images were quantified using ImageJ 
software (NIH). For quantifying fluorescence, the threshold of each picture was adjusted to 
the lowest possible value in the DAPI channel in order to measure total tissue area. The 
dextran threshold was fixed in each picture at a determined value based on the average 
intensity of all samples processed. The dextran-positive area was then normalized to the 
total tissue area in order to calculate the leakiness index. 
 
qPCR for circulating tumor cells 
Genomic DNA for blood was isolated using the QIAamp DNA Blood Mini Kit 
(Qiagen) and quantified using Prime Time qPCR assays (IDT). All samples were processed 
in triplicates. Each reaction consisted of 50 µl, containing 25 µl of iTaq Universal Supermix 
(BioRad), 2.5 µl of barcode primers and probe (Primer 1: 5'-ATC CAG AGG TTG ATT GTT 
CCA GAC GCG T-3', primer 2: 5'-CAG AAT CGT TGC CTG CAC ATC TTG GAA AC-3', 
FAM probe: 5'-/56-FAM/AAG GCT CGA /ZEN/GAC GTA GTC AGA CGT /3IABkFQ/-
3'), 2.5 µl of housekeeping (NM_172901.2) primers and probe (Primer 1: 5'-GAC TTG TAA 
CGG GCA GGC AGA TTG TG-3', primer 2: 5'-GAG GTG TGG GTC ACC TCG ACA TC-3', 
HEX probe: 5'-/5HEX/CCG TGT CGC /ZEN/TCT GAA GGG CAA TAT /3IABkFQ/-3, 
IDT) and 20 µl of gDNA sample (100 ng). The cycling conditions were 1 cycle of 
denaturation at 95 C for 3 min, followed by 40 cycles of amplification (95 C for 15 sec, 68 C 
for 1 min). Quantitative PCR analysis was performed on the Eppendorf Mastercycler ep 
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realplex. All signals were quantified using the ΔCt method and were normalized to the 
levels of the housekeeping gene. 
 
Tube formation assay 
96-well plates were coated with 50 ul of growth factor reduced Matrigel (BD 
Biosciences) and 5,000 cells were re-suspended in EBM-2 media and plated in each well. All 
cells were plated in four replicates. Morphological studies were performed after 8 hours 
using the Zeiss Axio Observer inverted microscope. 
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Chapter 5: Conclusions and Future Perspectives 
A transcriptional landscape of early human breast cancer 
 Very little is known about the genes that contribute to the development of DCIS and 
how they are altered to enable progression to invasive cancer. DCIS only progresses to 
invasive disease for less than half of the patients. Using laser capture microscopy and next-
generation sequencing technology, we isolated DCIS and IDC lesions from ten patient 
biopsies. We utilized RNAseq methods that are specific for low input samples and 
generated transcriptional profiles. We then examined for clustered and unique expression 
changes across these patient samples in order to identify early breast cancer subtypes and 
differentially expressed genes between DCIS and IDC.  
 Using hierarchical clustering of all expressed genes in our dataset, we identified 
clusters of largely normal, DCIS and IDC samples. We were able to observe that samples 
from the same patient clustered together if they represent the same grade DCIS. However, 
there were a few small subgroups in the clustering that did not fit cleanly into groups with 
similar pathology. With more samples, we will be able to determine if these samples 
represent small but repeatable subgroups or outliers. Furthermore, we were able to identify 
distinct breast cancer subtypes among the DCIS and IDC samples and thus we may 
therefore be able to predict disease progression based on these subtypes. Lastly, we were 
able to identify candidate genes that are differentially expressed in DCIS vs normal ducts 
and DCIS vs IDC. These genes could be markers that predict DCIS or invasiveness. Profiling 
more samples, we will eventually be able to identify an invasion specific signature. It will be 
important to follow-up on these candidate genes using mouse models of DCIS, such as the 
DCIS cell lines Mcf10DCIS and Sum-225 (Behbod et al. 2009).  
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In the future, we are planning to extend this to hundreds of patient biopsies in order 
to provide a more detailed transcriptional landscape of DCIS and early IDC. The key factor 
that will allow us to determine changes that are crucial to malignant progression lies in the 
long-term profiles from patients that did and did not go on to develop invasive disease. This 
allows stratification of patients that do not need intervention as well as the identification of 
key targets that might prevent further progression. Currently, we are working with our 
collaborators at Duke University to receive all clinical annotations of our patient samples.  
 In addition, current literature suggests that the stromal compartment surrounding 
invasive breast cancer could play a role in the progression of the disease. The break from 
DCIS to invasive carcinoma could be a result, not of the cancerous cells themselves, but of 
the stromal compartment (any connective tissue cells such as fibroblasts or immune cells) 
shifting to accommodate the expansion of tumor cells. We are planning to profile these 
stromal compartments using RNAseq in order to see if we are able to pick up stromal 
signatures in these neighboring cell types and whether the stromal compartment is different 
between DCIS and IDC samples.  
 
 A transcriptional landscape of disseminated and circulating tumor cells 
 Metastasis is a stepwise mechanism starting with tumor cells invading through the 
basement membrane, following intravasation into the blood or lymphatic system, survival 
in the blood stream, extravasation into distant organ sites, and finally colonization. The 
RNAseq transcriptome data of the 4T1 breast cancer cell lines from primary tumor cells, 
CTCs and metastatic tumor cells in lung and liver represents a broad overview of the gene 
expression levels at different stages of cancer progression and metastasis. We were able to 
identify Ptpn22 as a novel metastatic inducer that is overexpressed in the CTC cells 
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compared to the primary tumor. Knock-down of Ptpn22 in 4T1 cells greatly reduced the 
metastatic burden to the lung when these cells are injected orthotopically into the mammary 
gland. In addition, we were able to detect a reduction in the number of CTCs in the blood 
upon Ptpn22 knock-down and thus believe that Ptpn22 is pro-survival for these cells. Future 
experiments will need to be conducted in order to validate the exact mode of action. Using 
protein arrays, we are planning to identify substrates for Ptpn22. Another alternative to 
identify substrates of Ptpn22 might be substrate-trapping, in which catalytic inactive Ptpn22 
mutants are designed, which will bind to their tyrosine phosphorylated substrates (Flint et 
al. 1997). Most commonly the active cysteine residue of the signature motif is mutated to a 
serine residue. Substrates can be identified in vivo through co-immunoprecipitation or in 
vitro through GST pulldown and mass spectrometry. Moreover, overexpression of Ptpn22 in 
weakly metastatic cells such as 4T07 cells should be conducted in order to see if there is an 
increase in metastatic burden. In order to validate that overexpression of Ptpn22 in the CTC 
compartment is pro-survival in vivo, we are planning to overexpress pro-survival Bcl-2 in 
Pptn22 knocked-down 4T1 cells in order to see if this rescues the reduction of metastatic 
burden in the lung.  
The identification and characterization of differentially expressed genes in different 
stages of cancer progression, such as Ptpn22, will help identify novel drug target that inhibit 
metastasis formation. As low input RNAseq protocols are steadily improving, it is now 
feasible to do single-cell RNAseq libraries. This will further aid in the identification of drug 
targets, since we will be able to assess the heterogeneity of the CTC population. 
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A murine model of tumor heterogeneity  
The vast majority of recent studies focusing on tumor heterogeneity and how it 
influences metastatic disease progression have been retrospective in nature. Although, these 
studies often list putative drivers of specific clonal phenotypes, they are not able to validate 
them through functional genomics. We have developed a murine model of tumor 
heterogeneity that can be perturbed genetically to validate drivers of specific clonal 
behaviors. This model has the potential to elucidate drivers of all stages of tumor formation 
and metastasis. 
With this new technology we have found that a small subset of clones within the 
primary tumor are able to enter the cardiovascular system. These clones are not abundant in 
the primary tumor, and their ability to infiltrate the vascular system is not indicative of their 
ability to enter the lymphatic system. Furthermore, we demonstrated that these cells share 
the unique ability to perform vascular mimicry (VM), both in vivo and in vitro.  VM is a 
phenomenon wherein highly aggressive tumor cells differentiate to have endothelial-like 
phenotypes, allowing them to form channels that emanate from the tumor to the 
vasculature to distribute blood to hypoxic regions of the tumor.  
By performing expression profiling on these specialized cells, we have identified two 
serine protease inhibitors (Serpine2 and Slpi) that are both necessary and sufficient for the 
capacity of tumor cells to perform VM. We showed that these genes confer the same 
phenotypes in basal and claudin-low human breast cancer cell lines. Finally, through the 
analysis of clinical data, we showed that these genes are significantly up-regulated in breast 
cancer patients with relapse to the lung, as compared to non-relapsed patients. This 
represents a novel technology for identifying clinically relevant drivers of each stage of 
metastatic disease and highlights viable targets for the prevention of tumor cell 
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dissemination. Perhaps most importantly, these findings provide a logical basis for the 
selection of metastatic potential. Those changes in gene expression that feed the primary 
tumor with blood via vascular mimicry produce characteristics that promote metastasis to 
secondary sites. 
Vascular mimicry was initially identified in aggressive melanoma cells that were 
able to form tubular networks in three-dimensional culture systems (Maniotis et al. 1999). 
These observations were extended to melanoma xenograft models and biopsies of human 
aggressive melanoma, and then to other tumor types such as breast cancer (Shirakawa et al. 
2001). Later, investigators were able to show that these tubular structures contained viable 
blood flow using a xenograft model of inflammatory breast cancer (Shirakawa et al. 2002). A 
recent study conducted a meta-analysis of vascular mimicry and its association with poor 
prognosis in human cancer patients (Cao et al. 2013). Interestingly, vascular mimicry cancer 
patients show a poor 5-year overall survival (31%) compared to vascular mimicry negative 
patients (56%). Moreover metastatic melanoma patients had higher vascular mimicry rates 
(45%) than cancer patients with primary melanoma (23%). Thus it seems that vascular 
mimicry could contribute to metastasis formation in human cancer patients. Because the 
survival benefits of anti-angiogenic drugs have been modest so far in the clinic, it will be 
important to consider vascular mimicry in the design of anti-vascular therapies (Garber 
2002). For this, we are envisioning to combine anti-angiogenic drugs with knock-down of 
Serpine2 or Slpi in mice in order to see if it further reduces the lung metastatic burden.  
Slpi and Serpine2 have anti-coagulation effects, since these secreted proteins can 
bind and inhibit thrombin. We hypothesize that the vascular mimicry network has more 
leakiness than endothelial-lined vasculature and that the direct consequence is a higher rate 
of blood coagulation in these tubular structures. However, because of high expression of 
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Slpi and Serpine2, these cells are able to inhibit coagulation and can access free flowing 
blood within the vascular mimicry network. This fuels the primary tumor with oxygen and 
nutrients, and allows these cells to be drawn into the blood stream as circulating tumor cells, 
which can lead to metastasis formation. A recent publication from the Massagué group, 
identified other Serpins to be promoting cancer cell survival and angiogenesis once they 
have reached the brain during metastasis formation (Valiente et al. 2014). Interestingly, they 
also identified Serpine2 as one of the genes up-regulated in brain metastases compared to 
the primary tumor. However, they validated these genes through knock-down studies using 
intravenous injections into the blood stream in order to assess brain metastases. In these 
experiments, Serpine2 did not validate for the authors, since there was requirement for 
intravasation of these cells. Thus, it seems that Serpins in general have important functions 
in regulating metastasis formation and that approaches should be identified that will allow 
the targeting of multiple Serpins at once. 
Tumor heterogeneity is a major challenge in current clinical cancer therapy. It is a 
direct consequence of the adjustable nature of tumor cells, which allows them to adapt to a 
range of different environmental influences. Over the course of cancer progression, this 
leads to the development of a complex hierarchical structure of tumor subpopulations with 
various characteristics, such as in this case subpopulations that are efficient in VM. Current 
therapy often cannot take on the vast number of diverse cellular clones, which ultimately 
result in the dominance of a few clones. In order to improve treatment options for cancer 
patients, it is necessary to establish the ability to quickly characterize the impact of genomic 
alterations on the tumor and metastasis. We anticipate that our method is widely applicable 
to a variety of cancer types and hope that it can eventually be applied online to patient 
derived material. One future approach might be to take a small biopsy from a patient tumor, 
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introduce barcodes and then single-sort individual clonal lines. These clonal lines are then 
mixed and injected into mice in order to identify highly metastatic or resistant cell lineages. 
After elucidation of these vulnerabilities from these patient derived materials, one could 
adjust and personalize treatment strategies. In addition, this technology simultaneously 
allows the identification of novel drug targets that are specific to certain cell lineages.  
Another important aspect of heterogeneity is cooperativity between different clones. 
This is nicely shown in a study that uses Wnt1 induced mammary tumors in mice, which 
are composed of mixtures of basal and luminal cancer cells (Cleary et al. 2014). Interestingly, 
not luminal nor basal cancer cells are able to form mammary tumors by themselves, only in 
combination of both populations, they are able to induce tumor formation at a high rate. The 
authors were able to show that this is due to paracrine interaction of Wnt1 between both 
individual populations. In another study, which also highlights clonal cooperativity, the 
authors used the human cancer cell line MDA-MB-468 to generate a panel of 18 sub-clones 
that differed in overexpression of single secreted factors (Marusyk et al. 2014). They used 
these clones to generate monoclonal or polyclonal tumors in order to conduct clonal 
competition assays in vivo. They were able to show that tumor growth can be driven by a 
minor clonal population that expresses IL-11, which enhanced the proliferation of all tumor 
cells. Thus, in regards to our own heterogeneity model, it would be interesting to carry out 
competition assays with different combinations of clones. Clone T might for example be 
only effective in intravasating into the blood in the presence of a second clone.  
  
Identification of extravasation specific genes 
 In our murine model of tumor heterogeneity we were able to identify two clones, 
clone E and T, which were able to disseminate with equal efficiency to the cardiovascular 
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system. However, the majority of metastatic cells in the lung were composed solely of clone 
T. Thus, clone T is far more efficient in the extravasation process from the cardiovascular 
system to the lung, compared to clone E. We can exclude that this is a mere colonization 
phenotype of clone T since the number of secondary barcodes in clone T far exceeds that of 
clone E. We would like to exploit this observations and use clone T in an shRNA screen 
setting to identify genes that are necessary for extravasation.  For this, we want to compare 
the RNAseq profiles of clone E and T and identify genes that are overexpressed in clone T 
compared to clone E. These genes will be used in an shRNA screen in clone T and we will 
score the ability of these cells to extravasate from the blood to the lung, when injected into 
the tail vein of mice. We anticipate that this will result in the identification of novel genes 
that are specific for the extravasation process. By co-targeting one of these extravasation 
specific genes with Serpine2/Slpi, we think that we can drastically reduce the lung 
metastastic burden even more since we will be targeting both the intravasation and 
extravasation step of metastasis. 
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